var title_f19_49_20240="Mean effect size symptom rating PMDD";
var content_f19_49_20240=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F86227&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F86227&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Mean effect sizes and symptom ratings by premenstrual dysphoric disorder symptom or functioning measure and perimenstrual interval in 864 participants in the community sample",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Symptom*",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Symptom rating",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Effect size",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Day of peak",
"       </td>",
"       <td class=\"subtitle2\">",
"        Mean rating at peak",
"       </td>",
"       <td class=\"subtitle2\">",
"        (-6, -1)",
"       </td>",
"       <td class=\"subtitle2\">",
"        (-5, 1)",
"       </td>",
"       <td class=\"subtitle2\">",
"        (-4, 2)",
"       </td>",
"       <td class=\"subtitle2\">",
"        (-3, 3)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Physical symptoms, eg, bloating",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        2.87",
"       </td>",
"       <td class=\"centered\">",
"        0.33",
"       </td>",
"       <td class=\"centered\">",
"        0.49",
"       </td>",
"       <td class=\"centered\">",
"        0.58",
"       </td>",
"       <td class=\"centered\">",
"        0.62",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Food cravings",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        1.84",
"       </td>",
"       <td class=\"centered\">",
"        0.24",
"       </td>",
"       <td class=\"centered\">",
"        0.27",
"       </td>",
"       <td class=\"centered\">",
"        0.29",
"       </td>",
"       <td class=\"centered\">",
"        0.31",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low sex drive",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        1.90",
"       </td>",
"       <td class=\"centered\">",
"        0.21",
"       </td>",
"       <td class=\"centered\">",
"        0.27",
"       </td>",
"       <td class=\"centered\">",
"        0.29",
"       </td>",
"       <td class=\"centered\">",
"        0.29",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mood swings",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        1.83",
"       </td>",
"       <td class=\"centered\">",
"        0.20",
"       </td>",
"       <td class=\"centered\">",
"        0.26",
"       </td>",
"       <td class=\"centered\">",
"        0.28",
"       </td>",
"       <td class=\"centered\">",
"        0.29",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Change in appetite",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        1.85",
"       </td>",
"       <td class=\"centered\">",
"        0.15",
"       </td>",
"       <td class=\"centered\">",
"        0.20",
"       </td>",
"       <td class=\"centered\">",
"        0.23",
"       </td>",
"       <td class=\"centered\">",
"        0.24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Suddenly sad or tearful",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"       <td class=\"centered\">",
"        1.70",
"       </td>",
"       <td class=\"centered\">",
"        0.13",
"       </td>",
"       <td class=\"centered\">",
"        0.18",
"       </td>",
"       <td class=\"centered\">",
"        0.22",
"       </td>",
"       <td class=\"centered\">",
"        0.23",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Suddenly irritable",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        1.93",
"       </td>",
"       <td class=\"centered\">",
"        0.15",
"       </td>",
"       <td class=\"centered\">",
"        0.20",
"       </td>",
"       <td class=\"centered\">",
"        0.21",
"       </td>",
"       <td class=\"centered\">",
"        0.22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sensitive to rejection",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        1.74",
"       </td>",
"       <td class=\"centered\">",
"        0.15",
"       </td>",
"       <td class=\"centered\">",
"        0.18",
"       </td>",
"       <td class=\"centered\">",
"        0.20",
"       </td>",
"       <td class=\"centered\">",
"        0.20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Irritability that stayed with me",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        1.72",
"       </td>",
"       <td class=\"centered\">",
"        0.16",
"       </td>",
"       <td class=\"centered\">",
"        0.20",
"       </td>",
"       <td class=\"centered\">",
"        0.19",
"       </td>",
"       <td class=\"centered\">",
"        0.18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Easily upset",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        1.86",
"       </td>",
"       <td class=\"centered\">",
"        0.13",
"       </td>",
"       <td class=\"centered\">",
"        0.17",
"       </td>",
"       <td class=\"centered\">",
"        0.18",
"       </td>",
"       <td class=\"centered\">",
"        0.18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Symptoms interfered with getting things done at work",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        1.66",
"       </td>",
"       <td class=\"centered\">",
"        0.14",
"       </td>",
"       <td class=\"centered\">",
"        0.16",
"       </td>",
"       <td class=\"centered\">",
"        0.18",
"       </td>",
"       <td class=\"centered\">",
"        0.20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Felt \"on edge\"",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        1.73",
"       </td>",
"       <td class=\"centered\">",
"        0.12",
"       </td>",
"       <td class=\"centered\">",
"        0.16",
"       </td>",
"       <td class=\"centered\">",
"        0.17",
"       </td>",
"       <td class=\"centered\">",
"        0.17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Depressed mood",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        1.72",
"       </td>",
"       <td class=\"centered\">",
"        0.10",
"       </td>",
"       <td class=\"centered\">",
"        0.14",
"       </td>",
"       <td class=\"centered\">",
"        0.16",
"       </td>",
"       <td class=\"centered\">",
"        0.18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Symptoms interfered with relationships at home",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        1.60",
"       </td>",
"       <td class=\"centered\">",
"        0.09",
"       </td>",
"       <td class=\"centered\">",
"        0.15",
"       </td>",
"       <td class=\"centered\">",
"        0.16",
"       </td>",
"       <td class=\"centered\">",
"        0.17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wanted to be alone",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        1.86",
"       </td>",
"       <td class=\"centered\">",
"        0.12",
"       </td>",
"       <td class=\"centered\">",
"        0.15",
"       </td>",
"       <td class=\"centered\">",
"        0.16",
"       </td>",
"       <td class=\"centered\">",
"        0.16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Felt distractible",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        1.62",
"       </td>",
"       <td class=\"centered\">",
"        0.10",
"       </td>",
"       <td class=\"centered\">",
"        0.15",
"       </td>",
"       <td class=\"centered\">",
"        0.15",
"       </td>",
"       <td class=\"centered\">",
"        0.17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Symptoms interfered with relationships at work",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        1.63",
"       </td>",
"       <td class=\"centered\">",
"        0.14",
"       </td>",
"       <td class=\"centered\">",
"        0.15",
"       </td>",
"       <td class=\"centered\">",
"        0.15",
"       </td>",
"       <td class=\"centered\">",
"        0.16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Felt \"out of control\"",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        1.41",
"       </td>",
"       <td class=\"centered\">",
"        0.11",
"       </td>",
"       <td class=\"centered\">",
"        0.14",
"       </td>",
"       <td class=\"centered\">",
"        0.15",
"       </td>",
"       <td class=\"centered\">",
"        0.16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased interpersonal conflict",
"       </td>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"       <td class=\"centered\">",
"        1.61",
"       </td>",
"       <td class=\"centered\">",
"        0.13",
"       </td>",
"       <td class=\"centered\">",
"        0.15",
"       </td>",
"       <td class=\"centered\">",
"        0.15",
"       </td>",
"       <td class=\"centered\">",
"        0.13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Feelings of tension",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        2.12",
"       </td>",
"       <td class=\"centered\">",
"        0.10",
"       </td>",
"       <td class=\"centered\">",
"        0.14",
"       </td>",
"       <td class=\"centered\">",
"        0.15",
"       </td>",
"       <td class=\"centered\">",
"        0.15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No energy",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        2.25",
"       </td>",
"       <td class=\"centered\">",
"        0.05",
"       </td>",
"       <td class=\"centered\">",
"        0.10",
"       </td>",
"       <td class=\"centered\">",
"        0.14",
"       </td>",
"       <td class=\"centered\">",
"        0.18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Easily fatigued",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        2.18",
"       </td>",
"       <td class=\"centered\">",
"        0.04",
"       </td>",
"       <td class=\"centered\">",
"        0.10",
"       </td>",
"       <td class=\"centered\">",
"        0.14",
"       </td>",
"       <td class=\"centered\">",
"        0.17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Agitated",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        1.92",
"       </td>",
"       <td class=\"centered\">",
"        0.11",
"       </td>",
"       <td class=\"centered\">",
"        0.13",
"       </td>",
"       <td class=\"centered\">",
"        0.14",
"       </td>",
"       <td class=\"centered\">",
"        0.14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Negative thoughts about myself",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        1.61",
"       </td>",
"       <td class=\"centered\">",
"        0.10",
"       </td>",
"       <td class=\"centered\">",
"        0.15",
"       </td>",
"       <td class=\"centered\">",
"        0.14",
"       </td>",
"       <td class=\"centered\">",
"        0.14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Time missed from work",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        NA",
"       </td>",
"       <td class=\"centered\">",
"        0.06",
"       </td>",
"       <td class=\"centered\">",
"        0.10",
"       </td>",
"       <td class=\"centered\">",
"        0.14",
"       </td>",
"       <td class=\"centered\">",
"        0.13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Overeating",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        1.71",
"       </td>",
"       <td class=\"centered\">",
"        0.15",
"       </td>",
"       <td class=\"centered\">",
"        0.15",
"       </td>",
"       <td class=\"centered\">",
"        0.14",
"       </td>",
"       <td class=\"centered\">",
"        0.14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Symptoms interfered with social activities",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        1.62",
"       </td>",
"       <td class=\"centered\">",
"        0.07",
"       </td>",
"       <td class=\"centered\">",
"        0.11",
"       </td>",
"       <td class=\"centered\">",
"        0.14",
"       </td>",
"       <td class=\"centered\">",
"        0.15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Felt restless",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        1.74",
"       </td>",
"       <td class=\"centered\">",
"        0.09",
"       </td>",
"       <td class=\"centered\">",
"        0.12",
"       </td>",
"       <td class=\"centered\">",
"        0.14",
"       </td>",
"       <td class=\"centered\">",
"        0.14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Felt suddenly angry",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        1.68",
"       </td>",
"       <td class=\"centered\">",
"        0.09",
"       </td>",
"       <td class=\"centered\">",
"        0.12",
"       </td>",
"       <td class=\"centered\">",
"        0.13",
"       </td>",
"       <td class=\"centered\">",
"        0.11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arguments with people",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        1.36",
"       </td>",
"       <td class=\"centered\">",
"        0.11",
"       </td>",
"       <td class=\"centered\">",
"        0.13",
"       </td>",
"       <td class=\"centered\">",
"        0.13",
"       </td>",
"       <td class=\"centered\">",
"        0.12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Felt \"keyed up\"",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        1.59",
"       </td>",
"       <td class=\"centered\">",
"        0.09",
"       </td>",
"       <td class=\"centered\">",
"        0.12",
"       </td>",
"       <td class=\"centered\">",
"        0.13",
"       </td>",
"       <td class=\"centered\">",
"        0.11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased interest in usual activities",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        1.63",
"       </td>",
"       <td class=\"centered\">",
"        0.07",
"       </td>",
"       <td class=\"centered\">",
"        0.11",
"       </td>",
"       <td class=\"centered\">",
"        0.12",
"       </td>",
"       <td class=\"centered\">",
"        0.14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Symptoms interfered with getting things done at home",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        1.75",
"       </td>",
"       <td class=\"centered\">",
"        0.06",
"       </td>",
"       <td class=\"centered\">",
"        0.11",
"       </td>",
"       <td class=\"centered\">",
"        0.12",
"       </td>",
"       <td class=\"centered\">",
"        0.14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trouble sleeping",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        1.87",
"       </td>",
"       <td class=\"centered\">",
"        0.08",
"       </td>",
"       <td class=\"centered\">",
"        0.11",
"       </td>",
"       <td class=\"centered\">",
"        0.11",
"       </td>",
"       <td class=\"centered\">",
"        0.13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Less productive at home",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        1.89",
"       </td>",
"       <td class=\"centered\">",
"        0.05",
"       </td>",
"       <td class=\"centered\">",
"        0.09",
"       </td>",
"       <td class=\"centered\">",
"        0.11",
"       </td>",
"       <td class=\"centered\">",
"        0.13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Difficulty concentrating",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        1.81",
"       </td>",
"       <td class=\"centered\">",
"        0.05",
"       </td>",
"       <td class=\"centered\">",
"        0.08",
"       </td>",
"       <td class=\"centered\">",
"        0.11",
"       </td>",
"       <td class=\"centered\">",
"        0.13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Less productive at work",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        1.12",
"       </td>",
"       <td class=\"centered\">",
"        0.05",
"       </td>",
"       <td class=\"centered\">",
"        0.08",
"       </td>",
"       <td class=\"centered\">",
"        0.11",
"       </td>",
"       <td class=\"centered\">",
"        0.14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Symptoms interfered with getting things done at school",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        1.52",
"       </td>",
"       <td class=\"centered\">",
"        -0.04",
"       </td>",
"       <td class=\"centered\">",
"        0.06",
"       </td>",
"       <td class=\"centered\">",
"        0.10",
"       </td>",
"       <td class=\"centered\">",
"        0.14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Avoided social activities",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        1.53",
"       </td>",
"       <td class=\"centered\">",
"        0.04",
"       </td>",
"       <td class=\"centered\">",
"        0.07",
"       </td>",
"       <td class=\"centered\">",
"        0.09",
"       </td>",
"       <td class=\"centered\">",
"        0.10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anger that stayed with me",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        1.51",
"       </td>",
"       <td class=\"centered\">",
"        0.09",
"       </td>",
"       <td class=\"centered\">",
"        0.09",
"       </td>",
"       <td class=\"centered\">",
"        0.09",
"       </td>",
"       <td class=\"centered\">",
"        0.08",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Felt hopeless",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        1.48",
"       </td>",
"       <td class=\"centered\">",
"        0.05",
"       </td>",
"       <td class=\"centered\">",
"        0.07",
"       </td>",
"       <td class=\"centered\">",
"        0.08",
"       </td>",
"       <td class=\"centered\">",
"        0.09",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Slept too much",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        1.49",
"       </td>",
"       <td class=\"centered\">",
"        0.05",
"       </td>",
"       <td class=\"centered\">",
"        0.07",
"       </td>",
"       <td class=\"centered\">",
"        0.08",
"       </td>",
"       <td class=\"centered\">",
"        0.08",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Felt lonely",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        1.62",
"       </td>",
"       <td class=\"centered\">",
"        0.04",
"       </td>",
"       <td class=\"centered\">",
"        0.07",
"       </td>",
"       <td class=\"centered\">",
"        0.07",
"       </td>",
"       <td class=\"centered\">",
"        0.08",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Felt anxious",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        1.97",
"       </td>",
"       <td class=\"centered\">",
"        0.02",
"       </td>",
"       <td class=\"centered\">",
"        0.05",
"       </td>",
"       <td class=\"centered\">",
"        0.07",
"       </td>",
"       <td class=\"centered\">",
"        0.08",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Felt guilty",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        1.48",
"       </td>",
"       <td class=\"centered\">",
"        0.03",
"       </td>",
"       <td class=\"centered\">",
"        0.04",
"       </td>",
"       <td class=\"centered\">",
"        0.05",
"       </td>",
"       <td class=\"centered\">",
"        0.04",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Felt overwhelmed",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        1.91",
"       </td>",
"       <td class=\"centered\">",
"        0.01",
"       </td>",
"       <td class=\"centered\">",
"        0.04",
"       </td>",
"       <td class=\"centered\">",
"        0.04",
"       </td>",
"       <td class=\"centered\">",
"        0.05",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Time missed from class",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        NA",
"       </td>",
"       <td class=\"centered\">",
"        0.11",
"       </td>",
"       <td class=\"centered\">",
"        -1.01",
"       </td>",
"       <td class=\"centered\">",
"        0.03",
"       </td>",
"       <td class=\"centered\">",
"        0.06",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Symptoms interfered with relationships at school",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        1.64",
"       </td>",
"       <td class=\"centered\">",
"        0.09",
"       </td>",
"       <td class=\"centered\">",
"        -1.02",
"       </td>",
"       <td class=\"centered\">",
"        -0.05",
"       </td>",
"       <td class=\"centered\">",
"        0.01",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NA: not applicable.",
"     <br>",
"      * Symptoms are presented in descending order of severity and change during the last four days before and the first two days of the menstrual period.",
"      <br>",
"       <font class=\"bullet\">",
"        &bull;",
"       </font>",
"       Ratings are on a six-point scale: 1 indicates not at all; 2, minimal; 3, mild; 4, moderate; 5, severe; and 6, extreme.",
"       <br>",
"        &Delta; Effect size measures the increase in symptom endorsement during the perimenstrual interval compared with a nonmenstrual interval adjusted for the standard deviation of symptom endorsement during the entire cycle. The interval (-6, -1) indicates six days before through one day before menses; (-5, 1), five days before through the first day of menses; (-4, 2), four days before through the first two days of menses; and (-3, 3), three days before through the first three days of menses.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Hartlage SA, Freels S, Gotman N, Yonkers K. Criteria for Premenstrual Dysphoric Disorder. Arch Gen Psychiatry 2012; 69:300. Copyright &copy; 2012 American Medical Association. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_49_20240=[""].join("\n");
var outline_f19_49_20240=null;
var title_f19_49_20241="Diagnostic algorithm somatoform factitious malingering disorders";
var content_f19_49_20241=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F75973&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F75973&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 489px\">",
"   <div class=\"ttl\">",
"    Diagnostic algorithm for somatoform disorders, factitious disorder, and malingering",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 469px; height: 579px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_49_20241=[""].join("\n");
var outline_f19_49_20241=null;
var title_f19_49_20242="Contents: Gastrointestinal cancer";
var content_f19_49_20242=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?3/43/3774\">",
"       Oncology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Gastrointestinal cancer",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Gastrointestinal cancer",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Anus",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/33/1562\">",
"           Anal intraepithelial neoplasia: Diagnosis, screening, prevention, and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/29/12761\">",
"           Classification and epidemiology of anal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/54/38762\">",
"           Clinical features, staging, and treatment of anal cancer",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Appendix",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/14/36074\">",
"           Cancer of the appendix and pseudomyxoma peritonei",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/60/969\">",
"           Clinical characteristics of carcinoid tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/63/9206\">",
"           Clinical features of the carcinoid syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/30/43496\">",
"           Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/32/6665\">",
"           Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/46/39658\">",
"           Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/61/39897\">",
"           Treatment and surveillance of non-metastatic carcinoid tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/31/16888\">",
"           Treatment of the carcinoid syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Colon and rectum",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/55/30586\">",
"           Adjuvant chemotherapy for resected stage II colon cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/51/11066\">",
"           Adjuvant therapy for resected colon cancer in elderly patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/51/4922\">",
"           Adjuvant therapy for resected rectal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/44/34506\">",
"           Adjuvant therapy for resected stage III (node-positive) colon cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/62/32746\">",
"           Approach to the patient with colonic polyps",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/60/969\">",
"           Clinical characteristics of carcinoid tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/59/19386\">",
"           Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/63/9206\">",
"           Clinical features of the carcinoid syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/39/17016\">",
"           Clinical manifestations and diagnosis of familial adenomatous polyposis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/33/17946\">",
"           Clinical manifestations, diagnosis, and staging of colorectal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/7/25722\">",
"           Colorectal cancer surveillance in inflammatory bowel disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/25/42394\">",
"           Colorectal cancer: Epidemiology, risk factors, and protective factors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/49/36632\">",
"           Computed tomographic colonography",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/8/11400\">",
"           Diagnosis of the carcinoid syndrome and tumor localization",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/14/16618\">",
"           Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/29/19930\">",
"           Locoregional methods for management and palliation in patients who present with stage IV colorectal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/5/29783\">",
"           Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and management of patients and families",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/55/41850\">",
"           Management of potentially resectable colorectal cancer liver metastases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/30/43496\">",
"           Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/32/6665\">",
"           Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/46/39658\">",
"           Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/33/30234\">",
"           Molecular genetics of colorectal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/22/42346\">",
"           Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/36/28234\">",
"           Nonsurgical local treatment strategies for colorectal cancer liver metastases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/6/37990\">",
"           Overview of Peutz-Jeghers syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/15/38137\">",
"           Overview of surgical procedures for resectable primary rectal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/49/30489\">",
"           Overview of the management of primary colon cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/34/41514\">",
"           Pathology and prognostic determinants of colorectal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/9/3224\">",
"           Peutz-Jeghers syndrome and juvenile polyposis: Screening and management of patients and families",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/57/6041\">",
"           Pretreatment local staging evaluation for rectal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/10/37034\">",
"           Screening for colorectal cancer: Strategies in patients at average risk",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/41/9881\">",
"           Screening for colorectal cancer: Strategies in patients with possible increased risk due to family history",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/61/28634\">",
"           Surveillance after colorectal cancer resection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/32/44554\">",
"           Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/20/21833\">",
"           Systemic chemotherapy for metastatic colorectal cancer: General principles",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/1/44058\">",
"           Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/31/41466\">",
"           Therapy for metastatic colorectal cancer in elderly patients and those with a poor performance status",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/61/39897\">",
"           Treatment and surveillance of non-metastatic carcinoid tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/37/11866\">",
"           Treatment of locally advanced unresectable or recurrent rectal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/31/16888\">",
"           Treatment of the carcinoid syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Esophagus",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/34/33321\">",
"           Adjuvant and neoadjuvant imatinib for gastrointestinal stromal tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/10/44202\">",
"           Chemotherapy for locally advanced unresectable and metastatic esophageal and gastric cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/45/7898\">",
"           Diagnosis and staging of esophageal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/1/42006\">",
"           Endoscopic palliation of esophageal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/13/1242\">",
"           Endoscopic ultrasound for the characterization of subepithelial lesions of the upper gastrointestinal tract",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/35/35386\">",
"           Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/31/32250\">",
"           Epidemiology, pathobiology, and clinical manifestations of esophageal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/7/34938\">",
"           Local treatment for gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas of the gastrointestinal tract",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/25/30106\">",
"           Management of locally advanced unresectable esophageal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/60/20426\">",
"           Management of superficial esophageal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/51/39738\">",
"           Multimodality approaches to potentially resectable esophagogastric junction and gastric cardia adenocarcinomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/12/8391\">",
"           Pathogenesis of Barrett's esophagus and its malignant transformation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/31/39418\">",
"           Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/30/34282\">",
"           Surgical oncologic principles for management of resectable esophageal cancer",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hepatobiliary",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/24/43399\">",
"           Adjuvant treatment for localized, potentially resectable gallbladder cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/52/43848\">",
"           Ampullary carcinoma: Epidemiology, clinical manifestations, diagnosis and staging",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/37/3674\">",
"           Ampullary carcinoma: Treatment and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/10/34986\">",
"           Clinical features and diagnosis of primary hepatocellular carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/43/40633\">",
"           Clinical manifestations and diagnosis of cholangiocarcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/22/19816\">",
"           Endoscopic methods for the diagnosis of pancreatobiliary neoplasms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/38/25194\">",
"           Epidemiology and etiologic associations of hepatocellular carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/54/43881\">",
"           Epidemiology, pathogenesis, and classification of cholangiocarcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/46/15082\">",
"           Gallbladder cancer: Epidemiology, risk factors, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/32/36362\">",
"           Liver transplantation for hepatocellular carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/29/21978\">",
"           Management of potentially resectable hepatocellular carcinoma: Prognosis, role of neoadjuvant and adjuvant therapy, and posttreatment surveillance",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/18/36138\">",
"           Nonsurgical therapies for localized hepatocellular carcinoma: Radiofrequency ablation, percutaneous ethanol injection, thermal ablation, and cryoablation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/9/41114\">",
"           Nonsurgical therapies for localized hepatocellular carcinoma: Transarterial embolization, radiotherapy, and radioembolization",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/3/43063\">",
"           Overview of treatment approaches for hepatocellular carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/24/25992\">",
"           Staging and prognostic factors in hepatocellular carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/6/14442\">",
"           Surgical management of potentially resectable hepatocellular carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/32/10761\">",
"           Systemic therapy for advanced cholangiocarcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/61/39898\">",
"           Systemic treatment for advanced hepatocellular carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/11/33977\">",
"           Treatment of advanced, unresectable gallbladder cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/33/25114\">",
"           Treatment of localized cholangiocarcinoma: Surgical management and adjuvant therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/58/34728\">",
"           Treatment options for locally advanced cholangiocarcinoma",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Miscellaneous",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/63/39928\">",
"           Malignancy-related ascites",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/21/17754\">",
"           Malignant peritoneal mesothelioma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/48/35593\">",
"           Malignant peritoneal mesothelioma: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/53/29530\">",
"           PTEN hamartoma tumor syndrome, including Cowden syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pancreas",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/33/22042\">",
"           Adjuvant and neoadjuvant therapy for exocrine pancreatic cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/12/39114\">",
"           Chemotherapy for advanced exocrine pancreatic cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/57/18330\">",
"           Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/10/14504\">",
"           Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/40/41610\">",
"           Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/56/1929\">",
"           Endoscopic ultrasound in the staging of exocrine pancreatic cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/13/27866\">",
"           Epidemiology and risk factors for exocrine pancreatic cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/20/17735\">",
"           Exocrine pancreatic cancer: Palliation of symptoms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/57/31640\">",
"           Glucagonoma and the glucagonoma syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/30/12777\">",
"           Insulinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/51/6968\">",
"           Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/37/33370\">",
"           Management of locally advanced and borderline resectable exocrine pancreatic cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/30/43496\">",
"           Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/32/6665\">",
"           Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/46/39658\">",
"           Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/12/13513\">",
"           Molecular pathogenesis of exocrine pancreatic cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/27/44472\">",
"           Pathology of exocrine pancreatic neoplasms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/40/6794\">",
"           Pathology, classification, and grading of neuroendocrine tumors arising in the digestive system",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/34/3623\">",
"           Somatostatinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/34/8746\">",
"           Surgery in the treatment of exocrine pancreatic cancer and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/59/16311\">",
"           The VIPoma syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Small bowel",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/34/33321\">",
"           Adjuvant and neoadjuvant imatinib for gastrointestinal stromal tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/60/969\">",
"           Clinical characteristics of carcinoid tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/32/8714\">",
"           Clinical presentation and diagnosis of primary gastrointestinal lymphomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/43/10937\">",
"           Diagnosis and staging of small bowel neoplasms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/8/11400\">",
"           Diagnosis of the carcinoid syndrome and tumor localization",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/13/1242\">",
"           Endoscopic ultrasound for the characterization of subepithelial lesions of the upper gastrointestinal tract",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/35/35386\">",
"           Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/31/18938\">",
"           Epidemiology, clinical features, and types of small bowel neoplasms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/7/34938\">",
"           Local treatment for gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas of the gastrointestinal tract",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/53/3930\">",
"           Management of gastrointestinal lymphomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/30/43496\">",
"           Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/32/6665\">",
"           Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/46/39658\">",
"           Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/61/39897\">",
"           Treatment and surveillance of non-metastatic carcinoid tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/8/21642\">",
"           Treatment of small bowel neoplasms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/31/16888\">",
"           Treatment of the carcinoid syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Stomach",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/34/33321\">",
"           Adjuvant and neoadjuvant imatinib for gastrointestinal stromal tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/38/11882\">",
"           Adjuvant and neoadjuvant treatment of gastric cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/36/2634\">",
"           Association between Helicobacter pylori infection and gastrointestinal malignancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/60/969\">",
"           Clinical characteristics of carcinoid tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/36/11850\">",
"           Clinical features, diagnosis, and staging of gastric cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/32/8714\">",
"           Clinical presentation and diagnosis of primary gastrointestinal lymphomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/8/11400\">",
"           Diagnosis of the carcinoid syndrome and tumor localization",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/10/37033\">",
"           Early gastric cancer: Epidemiology, clinical manifestations, diagnosis, and staging",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/46/4842\">",
"           Early gastric cancer: Treatment, natural history, and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/13/1242\">",
"           Endoscopic ultrasound for the characterization of subepithelial lesions of the upper gastrointestinal tract",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/35/35386\">",
"           Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/19/2361\">",
"           Gastric polyps",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/15/2296\">",
"           Hereditary diffuse gastric cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/15/33018\">",
"           Invasive gastric cancer: Surgery and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/56/19333\">",
"           Local palliation for advanced gastric cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/7/34938\">",
"           Local treatment for gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas of the gastrointestinal tract",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/53/3930\">",
"           Management of gastrointestinal lymphomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/30/43496\">",
"           Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/32/6665\">",
"           Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/46/39658\">",
"           Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/26/33194\">",
"           Pathology and molecular pathogenesis of gastric cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/38/618\">",
"           Risk factors for gastric cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/52/6983\">",
"           Screening and prevention of gastric cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/61/39897\">",
"           Treatment and surveillance of non-metastatic carcinoid tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/31/16888\">",
"           Treatment of the carcinoid syndrome",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-59E160B39E-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f19_49_20242=[""].join("\n");
var outline_f19_49_20242=null;
var title_f19_49_20243="Vaginal hysterectomy PI";
var content_f19_49_20243=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F71521&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F71521&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 564px\">",
"   <div class=\"ttl\">",
"    Vaginal hysterectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 544px; height: 423px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a vaginal hysterectomy, the uterus and cervix are removed through the vagina. The top of the vagina is then sewn together. There are no visible scars. The ovaries and fallopian tubes may also be removed (called \"salpingo-oophorectomy\") at the same time, or may be left in place.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_49_20243=[""].join("\n");
var outline_f19_49_20243=null;
var title_f19_49_20244="Pinaverium: Patient drug information";
var content_f19_49_20244=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Pinaverium: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/17/41234?source=see_link\">",
"     see \"Pinaverium: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F210072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dicetel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat irritable bowel syndrome.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702743",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to pinaverium or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701033",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to lactose, talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697889",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain or heartburn.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699050",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling or pain of hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699006",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain or bloody loose stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694729",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not lie down for at least 30 minutes after taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12045 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-7727F3B860-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_49_20244=[""].join("\n");
var outline_f19_49_20244=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210072\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030088\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030087\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030092\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030093\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030095\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030090\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030091\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030096\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030097\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/17/41234?source=related_link\">",
"      Pinaverium: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_49_20245="Alfacalcidol: Patient drug information";
var content_f19_49_20245=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Alfacalcidol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/14/37093?source=see_link\">",
"     see \"Alfacalcidol: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F11820952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      One-Alpha&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F12676139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F11822934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691428",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop and treat low calcium levels.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F11822933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to alfacalcidol or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: High calcium levels, high phosphate levels, or high vitamin D levels.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F11822938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696860",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take cholestyramine, mineral oil, antacids that have magnesium, or orlistat with this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F11822939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698141",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High calcium level. Signs include weakness, confusion, feeling tired, headache, upset stomach and throwing up, hard stools (constipation), or bone pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F11822941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F11822936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695679",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Stop other vitamins that have vitamin D.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302890",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and diet aid plan that your doctor told you about.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695700",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow capsule whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F11822937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F11822942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store capsules at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699433",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store liquid (solution) in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F11822943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16468 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-E9920BD3B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_49_20245=[""].join("\n");
var outline_f19_49_20245=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11820952\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12676139\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11822934\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11822933\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11822938\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11822939\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11822941\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11822936\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11822937\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11822942\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11822943\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/14/37093?source=related_link\">",
"      Alfacalcidol: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_49_20246="Internuclear ophthalmoplegia";
var content_f19_49_20246=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Internuclear ophthalmoplegia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/49/20246/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/49/20246/contributors\">",
"     Teresa C Frohman, BS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/49/20246/contributors\">",
"     Elliot M Frohman, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/49/20246/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/49/20246/contributors\">",
"     Paul W Brazis, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/49/20246/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/49/20246/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/49/20246/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 2, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Internuclear ophthalmoplegia (INO) is a specific gaze abnormality characterized by impaired horizontal eye movement with weak adduction of the affected eye and abduction nystagmus of the contralateral eye. It is one of the most localizing brainstem syndromes, resulting from a lesion in the medial longitudinal fasciculus (MLF) in the dorsomedial brainstem tegmentum of either the pons or the midbrain [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20246/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OCULOMOTOR CIRCUITRY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Foveation or visual targeting with binocular fusion and stereoscopy (depth perception) requires highly synchronous eye movements that place objects of visual interest on the corresponding points of both retinas. This process is dependent upon the precise coordination between cranial nerves III, IV, and VI and their interneuronal pathways that project through the medial longitudinal fasciculus (MLF) (",
"    <a class=\"graphic graphic_figure graphicRef62010 \" href=\"UTD.htm?25/8/25734\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The paramedian pontine reticular formation (PPRF) is often referred to as the conjugate gaze center for horizontal eye movements. During horizontal eye movement, the PPRF burst cells innervate the abducens nucleus, which contains two distinctive sets of neurons. Axons from the abducens motorneurons innervate the ipsilateral lateral rectus muscle. Axons of the abducens interneurons cross the midline to become the MLF and subsequently innervate the medial rectus subnucleus of the oculomotor complex (cranial nerve nucleus III) and finally the medial rectus muscle.",
"   </p>",
"   <p>",
"    The MLF exists as a pair of white matter fiber tracts that lie near the midline just under the fourth ventricle and cerebral aqueduct and extend through the dorsomedial pontine and midbrain tegmentum. Because of their close physical proximity, bilateral injury is common.",
"   </p>",
"   <p>",
"    An internuclear ophthalmoplegia (INO) results from injury to the MLF within the dorsomedial pontine or midbrain tegmentum. The side of the INO is named by the side of the adduction deficit, which is ipsilateral to the medial longitudinal fasciculus (MLF) lesion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SYMPTOMS AND SIGNS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with internuclear ophthalmoplegia (INO) may complain of horizontal diplopia when there is a significant adduction weakness or limitation on lateral gaze [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20246/abstract/2\">",
"     2",
"    </a>",
"    ]. Diplopia is not usually present in primary gaze. The dysconjugate movement of the two eyes during horizontal gaze results in an interruption in binocular fusion that can lead to visual confusion, oscillopsia, diplopia, reading fatigue, and loss of stereopsis (depth perception) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20246/abstract/3\">",
"     3",
"    </a>",
"    ]. Some patients also complain of vertigo [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20246/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Important findings on examination include impaired adduction on lateral gaze, with nystagmus in the contralateral, abducting eye. Other signs may also be observed:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Adduction weakness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depending on the severity of the lesion, adduction of the involved eye may be impaired or absent. In milder forms, the deficit may be limited to a decrease in adduction velocity without ocular limitation (",
"    <a class=\"graphic graphic_figure graphicRef53437 \" href=\"UTD.htm?4/36/4676\">",
"     figure 2",
"    </a>",
"    ). Evidence of milder forms of INO may be best elicited by asking the patient to perform fast horizontal eye movements (saccades) away from a fixed central point. Interruption of the ascending axons that arise from the internuclear neurons in the abducens nucleus likely explains the observed adduction deficit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Normal convergence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most lesions of the medial longitudinal fasciculus (MLF) are located in the pons or caudal mesencephalon, sparing the vergence pathways, including the fibers deriving from the medial rectus subnucleus of cranial nerve III [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20246/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. As a result, convergence is intact in the majority of patients despite adduction weakness on lateral gaze. This finding can help distinguish an INO from a partial third nerve palsy (see",
"    <a class=\"local\" href=\"#H16\">",
"     'Differential diagnosis'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Abduction nystagmus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The contralateral abducting eye will usually exhibit a disassociated horizontal nystagmus, although this does not always occur.",
"   </p>",
"   <p>",
"    The underlying mechanisms causing abducting nystagmus are unknown. There is evidence that more than one mechanism may play a role in different patients and even in the same patient [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20246/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One theory with empiric support is that abduction nystagmus results from an adaptive response to overcome the weakness of the contralateral medial rectus [",
"      <a class=\"abstract\" href=\"UTD.htm?19/49/20246/abstract/5,6\">",
"       5,6",
"      </a>",
"      ]. This is explained by Hering's law of equal innervation, which states that attempts to increase innervation to the weak muscle in one eye are accompanied by a commensurate increase in innervation to the yoke muscle in the other eye.",
"     </li>",
"     <li>",
"      Alternatively, gaze-evoked nystagmus may occur in patients with INO because of involvement of adjacent structures, such as the vestibular nuclei [",
"      <a class=\"abstract\" href=\"UTD.htm?19/49/20246/abstract/5\">",
"       5",
"      </a>",
"      ]. The nystagmus is dissociated because adductor weakness limits its manifestation in the affected eye. Subclinical nystagmus in the adducting eye has been demonstrated with electro-ocular techniques [",
"      <a class=\"abstract\" href=\"UTD.htm?19/49/20246/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Abduction slowing",
"    </span>",
"    &nbsp;&mdash;&nbsp;INO can produce slowing of abduction as well as adduction in the affected eye [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20246/abstract/5,8\">",
"     5,8",
"    </a>",
"    ]. This small degree of abduction slowing is expected in the context of adduction weakness, because of the loss of the contribution of the off-pulse of innervation (defective relaxation) when the medial rectus acts as an antagonist [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20246/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Abnormal vertical eye movements",
"    </span>",
"    &nbsp;&mdash;&nbsp;The MLF also contains pathways involved in the regulation of vertical pursuit, vertical vestibular signals, and vertical alignment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20246/abstract/2,10-14\">",
"     2,10-14",
"    </a>",
"    ]. Patients with INO will therefore often exhibit abnormalities with vertical eye movements, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diminished vertical gaze holding",
"     </li>",
"     <li>",
"      Abnormal optokinetic and pursuit responses",
"     </li>",
"     <li>",
"      Suppressed vestibular ocular reflex (VOR)",
"     </li>",
"     <li>",
"      Vertical gaze-evoked nystagmus",
"     </li>",
"     <li>",
"      Skew deviation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      contraversive ocular tilt reaction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These signs are inconsistently present and are not required for the diagnosis of INO [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20246/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Associated syndromes",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     One-and-a-half syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;This syndrome consists of a gaze palsy in one direction with an INO on horizontal gaze in the opposite direction. With attempted horizontal gaze, only abduction of the contralateral eye remains. Convergence is also spared. This syndrome is produced by damage to the paramedian reticular formation (PPRF)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    abducens nucleus and MLF on the same side.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Wall-eyed bilateral INO",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the lesion affects the MLF within the upper midbrain, vergence pathways and the oculomotor apparatus can be disrupted, resulting in a variety of eye movement abnormalities that include impaired convergence [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20246/abstract/5,6,8,16\">",
"     5,6,8,16",
"    </a>",
"    ]. These lesions are typically bilateral and produce divergence of the eyes (wall-eyed).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many potential causes of internuclear ophthalmoplegia (INO) (",
"    <a class=\"graphic graphic_table graphicRef78378 \" href=\"UTD.htm?25/22/25963\">",
"     table 1",
"    </a>",
"    ). Most cases (approximately 70 percent) of INO are due to multiple sclerosis or cerebrovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20246/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Multiple sclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple sclerosis (MS) underlies approximately one-third of cases of INO and is the most common cause in a young person (&lt;45 years). The deficit is bilateral in most (73 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20246/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    INO is also the most common eye movement abnormality in MS. The reported prevalence of INO among patients with MS varies between 17 and 41 percent of patients, depending in part on whether the INO is a clinical manifestation or an incidental finding on examination, as well as the techniques used to elicit this finding (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Specialized neuroophthalmologic techniques'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20246/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. The periventricular location of the medial longitudinal fasciculus is thought to make this area particularly susceptible to autoimmune inflammatory demyelination [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20246/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Cerebrovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common cause of INO in an older patient is ischemic infarction. These patients are typically older than patients with MS, with an average age of 62 to 66 years [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20246/abstract/2,21\">",
"     2,21",
"    </a>",
"    ]. In addition to advanced age, vascular risk factors (hypertension, diabetes, smoking) are prevalent in these patients. In contrast to MS, most (87 to 93 percent) INO in this setting is unilateral [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20246/abstract/2,17\">",
"     2,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The underlying stroke subtype is usually small artery occlusion or lacunar disease involving the penetrating arteries originating from the basilar artery. Large branch artery occlusions in the basilar, superior cerebellar, and posterior cerebral arteries have also been associated with infarctions producing INO [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20246/abstract/2\">",
"     2",
"    </a>",
"    ]. In large case series, individual cases of INO are reported with many other stroke subtypes, including hemorrhage (hypertensive, vascular malformation), vertebral artery dissection, temporal arteritis, and other vasculitides [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20246/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More than half of patients with an INO due to brainstem infarction have other neurologic symptoms and signs in addition to INO, including sensory deficits, dysarthria, gait ataxia, and lower-motor neuron facial palsy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20246/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large number of causes make up the one-quarter to one-third of INO cases that are not due to MS or cerebrovascular disease (",
"    <a class=\"graphic graphic_table graphicRef78378 \" href=\"UTD.htm?25/22/25963\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20246/abstract/12,17\">",
"     12,17",
"    </a>",
"    ]. The most common of these are infection, trauma, and tumor. In some remarkable cases, mild head injury can produce an isolated unilateral or bilateral INO [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20246/abstract/22-24\">",
"     22-24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A partial third nerve palsy with prominent medial rectus weakness may be confused with an internuclear ophthalmoplegia (INO). Distinguishing features include other third nerve deficits (weakness of elevation, ptosis, pupil dilation), impaired convergence, and absence of the contralateral abduction nystagmus, all of which point to a third nerve palsy rather than an INO. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36856?source=see_link\">",
"     \"Third cranial nerve (oculomotor nerve) palsy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are reports of eye movement abnormalities in progressive supranuclear palsy (PSP) that suggest bilateral INO [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20246/abstract/25\">",
"     25",
"    </a>",
"    ]. Parkinsonism and other features of PSP are present in these individuals, and the eye movement abnormality can be overcome with oculocephalic maneuvers in PSP (because the lesion is supranuclear) but not in an INO. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/36/15943?source=see_link\">",
"     \"Bradykinetic movement disorders in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A pseudo-internuclear ophthalmoplegia is a well-described phenomenon in patients with myasthenia gravis and Guillain-Barr&eacute; syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20246/abstract/15,17,26-28\">",
"     15,17,26-28",
"    </a>",
"    ]. In practice, this is most often observed in the setting of an established diagnosis of these disorders, but can be observed at first presentation. The presence of ptosis and lid fatigue will alert the clinician to myasthenia, while areflexia, often with ataxia or limb weakness, will suggest the Miller-Fisher variant of Guillain-Barr&eacute; syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/22/5481?source=see_link\">",
"     \"Clinical features and diagnosis of Guillain-Barr&eacute; syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17206?source=see_link\">",
"     \"Clinical manifestations of myasthenia gravis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Findings suggestive of bilateral INO have also been reported in the setting of drug overdose; however, these individuals universally have an impaired level of consciousness [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20246/abstract/17,29\">",
"     17,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who present with an internuclear ophthalmoplegia (INO) require brain magnetic resonance imaging (MRI) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20246/abstract/30\">",
"     30",
"    </a>",
"    ]. A normal brain MRI should suggest an alternative cause of the extraocular movement disorder or pseudo-INO. Contrast-enhancement and other specialized MRI sequences may enhance sensitivity, depending on the most likely etiology:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 58 patients with multiple sclerosis (MS) and INO, all had an abnormality within the region of the medial longitudinal fasciculus (MLF) on proton density imaging; other MRI sequences (T2-weighted, FLAIR) were less sensitive [",
"      <a class=\"abstract\" href=\"UTD.htm?19/49/20246/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another case series described MRI findings in 30 patients with brainstem infarction [",
"      <a class=\"abstract\" href=\"UTD.htm?19/49/20246/abstract/2\">",
"       2",
"      </a>",
"      ]. In two cases, diffusion-weighted MRI identified an acute infarction that was not detected on T2-weighted MRI.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Specialized neuroophthalmologic techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subtle forms of INO can be overlooked on examination and may only be evident on formal oculographic recording, which measures the velocity and acceleration of abduction and adduction [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20246/abstract/7,15,18,31\">",
"     7,15,18,31",
"    </a>",
"    ]. Compared with these quantitative oculographic techniques, the accuracy of clinical examination by clinicians to detect an INO was imperfect (with both false positives and negatives), even by neuroophthalmologists [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20246/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neurologic examination for INO can be improved by the use of an opticokinetic (OKN) tape. This is a highly sensitive technique for observing subtle adduction slowing in INO, and allows more effective observation of saccadic dysconjugacy during the fast phase of nystagmus [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20246/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This specialized testing may have clinical utility in the setting of possible multiple sclerosis, in which the identification of a second site of neurologic abnormality can influence diagnosis and treatment decisions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     PROGNOSIS AND TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The deficits associated with internuclear ophthalmoplegia (INO) often resolve over a few to several months [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20246/abstract/12\">",
"     12",
"    </a>",
"    ]. In one series, patients with a cerebrovascular origin were less likely to recover; 63 percent had persistent symptoms after three years. However, others have observed a better prognosis with INO due to brainstem infarction, with 79 to 87 percent recovery in two to three months [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20246/abstract/2,21\">",
"     2,21",
"    </a>",
"    ]. Restricted neurologic deficits and absence of a lesion on T2-weighted magnetic resonance imaging (MRI) appear to be associated with a better prognosis of recovery from INO in stroke patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20246/abstract/2,12,21\">",
"     2,12,21",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    Patients may be treated with patching of one eye for symptomatic relief of diplopia. Since the double vision is typically only in eccentric gaze, the use of prisms is usually not helpful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Internuclear ophthalmoplegia (INO) is a specific gaze abnormality, characterized by impaired horizontal eye movement with weak adduction of the affected eye and abduction nystagmus of the contralateral eye. In typical cases, convergence is spared. Abnormalities of vertical gaze are common but are not required features of an INO (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Symptoms and signs'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      An INO is one of the most localizing brainstem syndromes, resulting from a lesion in the medial longitudinal fasciculus in the dorsomedial brainstem tegmentum of either the pons or the midbrain. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Oculomotor circuitry'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      More than two-thirds of cases result from multiple sclerosis (MS) or cerebrovascular disease. Patients with MS are typically young (less than 45 years), and the INO is usually bilateral. Patients with cerebrovascular disease are rarely less than 45 years old, have prevalent vascular risk factors, and are more likely to have a unilateral INO. Infections, tumors, and trauma cause most other cases. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Causes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An INO can be confused with a partial third nerve palsy, other supranuclear gaze disturbances, or peripheral neuromuscular disease, especially ocular myasthenia gravis. However, a careful neurologic examination can usually distinguish between these entities. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients who present with INO require brain magnetic resonance imaging (MRI). Contrast-enhancement and other specialized MRI sequences can increase the sensitivity of MRI for specific diagnoses. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients will recover within a few to several months. However, some will have deficits that persist for greater than one year. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Prognosis and treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20246/abstract/1\">",
"      Frohman EM, Zhang H, Kramer PD, et al. MRI characteristics of the MLF in MS patients with chronic internuclear ophthalmoparesis. Neurology 2001; 57:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20246/abstract/2\">",
"      Kim JS. Internuclear ophthalmoplegia as an isolated or predominant symptom of brainstem infarction. Neurology 2004; 62:1491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20246/abstract/3\">",
"      Mills DA, Frohman TC, Davis SL, et al. Break in binocular fusion during head turning in MS patients with INO. Neurology 2008; 71:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20246/abstract/4\">",
"      Frohman EM, Frohman TC, Zee DS, et al. The neuro-ophthalmology of multiple sclerosis. Lancet Neurol 2005; 4:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20246/abstract/5\">",
"      Zee DS, Hain TC, Carl JR. Abduction nystagmus in internuclear ophthalmoplegia. Ann Neurol 1987; 21:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20246/abstract/6\">",
"      Baloh RW, Yee RD, Honrubia V. Internuclear ophthalmoplegia. I. Saccades and dissociated nystagmus. Arch Neurol 1978; 35:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20246/abstract/7\">",
"      Flipse JP, Straathof CS, Van der Steen J, et al. Binocular saccadic eye movements in multiple sclerosis. J Neurol Sci 1997; 148:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20246/abstract/8\">",
"      Zee DS. Internuclear ophthalmoplegia: pathophysiology and diagnosis. Baillieres Clin Neurol 1992; 1:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20246/abstract/9\">",
"      Bronstein AM, Rudge P, Gresty MA, et al. Abnormalities of horizontal gaze. Clinical, oculographic and magnetic resonance imaging findings. II. Gaze palsy and internuclear ophthalmoplegia. J Neurol Neurosurg Psychiatry 1990; 53:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20246/abstract/10\">",
"      Evinger LC, Fuchs AF, Baker R. Bilateral lesions of the medial longitudinal fasciculus in monkeys: effects on the horizontal and vertical components of voluntary and vestibular induced eye movements. Exp Brain Res 1977; 28:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20246/abstract/11\">",
"      Ranalli PJ, Sharpe JA. Vertical vestibulo-ocular reflex, smooth pursuit and eye-head tracking dysfunction in internuclear ophthalmoplegia. Brain 1988; 111 ( Pt 6):1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20246/abstract/12\">",
"      Bola&ntilde;os I, Lozano D, Cant&uacute; C. Internuclear ophthalmoplegia: causes and long-term follow-up in 65 patients. Acta Neurol Scand 2004; 110:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20246/abstract/13\">",
"      Cremer PD, Migliaccio AA, Halmagyi GM, Curthoys IS. Vestibulo-ocular reflex pathways in internuclear ophthalmoplegia. Ann Neurol 1999; 45:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20246/abstract/14\">",
"      Zwergal A, Cnyrim C, Arbusow V, et al. Unilateral INO is associated with ocular tilt reaction in pontomesencephalic lesions: INO plus. Neurology 2008; 71:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20246/abstract/15\">",
"      Keane, JR. Internuclear ophthalmoplegia - a reply. Arch Neurol 2006; 63:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20246/abstract/16\">",
"      Jung DS, Park KP. Posttraumatic bilateral internuclear ophthalmoplegia with exotropia. Arch Neurol 2004; 61:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20246/abstract/17\">",
"      Keane JR. Internuclear ophthalmoplegia: unusual causes in 114 of 410 patients. Arch Neurol 2005; 62:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20246/abstract/18\">",
"      M&uuml;ri RM, Meienberg O. The clinical spectrum of internuclear ophthalmoplegia in multiple sclerosis. Arch Neurol 1985; 42:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20246/abstract/19\">",
"      Meienberg O, M&uuml;ri R, Rabineau PA. Clinical and oculographic examinations of saccadic eye movements in the diagnosis of multiple sclerosis. Arch Neurol 1986; 43:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20246/abstract/20\">",
"      Frohman EM, Frohman TC, O'Suilleabhain P, et al. Quantitative oculographic characterisation of internuclear ophthalmoparesis in multiple sclerosis: the versional dysconjugacy index Z score. J Neurol Neurosurg Psychiatry 2002; 73:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20246/abstract/21\">",
"      Eggenberger E, Golnik K, Lee A, et al. Prognosis of ischemic internuclear ophthalmoplegia. Ophthalmology 2002; 109:1676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20246/abstract/22\">",
"      Gray OM, Forbes RB, Morrow JI. Primary isolated brainstem injury producing internuclear ophthalmoplegia. Br J Neurosurg 2001; 15:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20246/abstract/23\">",
"      Constantoyannis C, Tzortzidis F, Papadakis N. Internuclear ophthalmoplegia following minor head injury: a case report. Br J Neurosurg 1998; 12:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20246/abstract/24\">",
"      Matsumoto H, Ohminami S, Goto J, Tsuji S. Progressive supranuclear palsy with wall-eyed bilateral internuclear ophthalmoplegia syndrome. Arch Neurol 2008; 65:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20246/abstract/25\">",
"      Flint AC, Williams O. Bilateral internuclear ophthalmoplegia in progressive supranuclear palsy with an overriding oculocephalic maneuver. Mov Disord 2005; 20:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20246/abstract/26\">",
"      al-Din SN, Anderson M, Eeg-Olofsson O, Trontelj JV. Neuro-ophthalmic manifestations of the syndrome of ophthalmoplegia, ataxia and areflexia: a review. Acta Neurol Scand 1994; 89:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20246/abstract/27\">",
"      Davis TL, Lavin PJ. Pseudo one-and-a-half syndrome with ocular myasthenia. Neurology 1989; 39:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20246/abstract/28\">",
"      Korkmaz A, Topaloglu H, Kansu T. Wall eyed bilateral internuclear ophthalmoplegia in chronic inflammatory demyelinating polyneuropathy. Eur J Neurol 2002; 9:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20246/abstract/29\">",
"      Lifshitz M, Gavrilov V, Sofer S. Signs and symptoms of carbamazepine overdose in young children. Pediatr Emerg Care 2000; 16:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20246/abstract/30\">",
"      Atlas SW, Grossman RI, Savino PJ, et al. Internuclear ophthalmoplegia: MR-anatomic correlation. AJNR Am J Neuroradiol 1987; 8:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20246/abstract/31\">",
"      Solingen LD, Baloh RW, Myers L, Ellison G. Subclinical eye movement disorders in patients with multiple sclerosis. Neurology 1977; 27:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20246/abstract/32\">",
"      Frohman TC, Frohman EM, O'Suilleabhain P, et al. Accuracy of clinical detection of INO in MS: corroboration with quantitative infrared oculography. Neurology 2003; 61:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20246/abstract/33\">",
"      SMITH JL, DAVID NJ. INTERNUCLEAR OPHTHALMOPLEGIA. TWO NEW CLINICAL SIGNS. Neurology 1964; 14:307.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5239 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-D40D2B0C78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_49_20246=[""].join("\n");
var outline_f19_49_20246=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OCULOMOTOR CIRCUITRY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SYMPTOMS AND SIGNS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Adduction weakness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Normal convergence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Abduction nystagmus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Abduction slowing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Abnormal vertical eye movements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Associated syndromes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - One-and-a-half syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Wall-eyed bilateral INO",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Multiple sclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Cerebrovascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Others",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Specialized neuroophthalmologic techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      PROGNOSIS AND TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5239\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5239|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/8/25734\" title=\"figure 1\">",
"      Oculomotor circuitry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/36/4676\" title=\"figure 2\">",
"      Internuclear ophthalmoplegia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5239|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/22/25963\" title=\"table 1\">",
"      Causes of INO",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/36/15943?source=related_link\">",
"      Bradykinetic movement disorders in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/22/5481?source=related_link\">",
"      Clinical features and diagnosis of Guillain-Barr&eacute; syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17206?source=related_link\">",
"      Clinical manifestations of myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36856?source=related_link\">",
"      Third cranial nerve (oculomotor nerve) palsy in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_49_20247="Surg ulcerative colitis";
var content_f19_49_20247=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F52597&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F52597&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Surgical options for ulcerative colitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 625px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_49_20247=[""].join("\n");
var outline_f19_49_20247=null;
var title_f19_49_20248="Urea cycle disorders: Clinical features and diagnosis";
var content_f19_49_20248=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Urea cycle disorders: Clinical features and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/49/20248/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/49/20248/contributors\">",
"     Brendan Lee, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/49/20248/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/49/20248/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/49/20248/contributors\">",
"     Sihoun Hahn, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/49/20248/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/49/20248/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/49/20248/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The urea cycle is the metabolic pathway that transforms nitrogen to urea for excretion from the body (",
"    <a class=\"graphic graphic_figure graphicRef60652 \" href=\"UTD.htm?2/49/2832\">",
"     figure 1",
"    </a>",
"    ). Deficiency of an enzyme in the pathway causes a urea cycle disorder (UCD). The urea cycle disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20248/abstract/1\">",
"     1",
"    </a>",
"    ] are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Carbamyl phosphate synthetase I (CPSI) deficiency (MIM #237300)",
"     </li>",
"     <li>",
"      Ornithine transcarbamylase (OTC) deficiency (MIM #311250)",
"     </li>",
"     <li>",
"      Argininosuccinate synthetase (ASS) deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?19/49/20248/abstract/2\">",
"       2",
"      </a>",
"      ] (also known as classic citrullinemia or type I citrullinemia, CTLN1, MIM #215700)",
"     </li>",
"     <li>",
"      Argininosuccinate lyase (ASL) deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?19/49/20248/abstract/3\">",
"       3",
"      </a>",
"      ] (also known as argininosuccinic aciduria, MIM #207900)",
"     </li>",
"     <li>",
"      N-acetyl glutamate synthetase (NAGS) deficiency (MIM#237310)",
"     </li>",
"     <li>",
"      Arginase deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?19/49/20248/abstract/4\">",
"       4",
"      </a>",
"      ] (MIM #207800)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    UCDs, except for arginase deficiency, result in hyperammonemia and life-threatening metabolic decompensations in infancy. Survivors of the metabolic decompensation frequently have severe neurologic injury. Prompt recognition and treatment are needed to improve outcome.",
"   </p>",
"   <p>",
"    An overview of the clinical features and diagnosis of urea cycle disorders is presented here. The management of urea cycle disorders is discussed separately. A general overview of inborn errors of metabolism is also presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/49/19225?source=see_link\">",
"     \"Urea cycle disorders: Management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27047?source=see_link\">",
"     \"Inborn errors of metabolism: Classification\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24489?source=see_link\">",
"     \"Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=see_link\">",
"     \"Inborn errors of metabolism: Metabolic emergencies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;UCDs occur in approximately 1 in 8200 live births in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20248/abstract/5\">",
"     5",
"    </a>",
"    ]. The incidence of UCDs among the offspring of employees of a large Saudi company in the Eastern Province of Saudi Arabia was 1 in 14,285 live births. However, this incidence is suspected to be an underestimation, since patients were evaluated based upon clinical manifestations",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    family history rather than newborn screening [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20248/abstract/6\">",
"     6",
"    </a>",
"    ]. UCDs appear to be less common in Finland, with a reported incidence of 1 in 39,000 live births.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The urea cycle converts nitrogen from peripheral (muscle) and enteral sources (protein ingestion) into urea that is water soluble and can be excreted. Two moles of nitrogen, one from ammonia and one from aspartate, are converted to urea in each cycle (",
"    <a class=\"graphic graphic_figure graphicRef60652 \" href=\"UTD.htm?2/49/2832\">",
"     figure 1",
"    </a>",
"    ). Ammonia nitrogen derives from circulating amino acids, mostly glutamine and alanine. Aspartate is a substrate for argininosuccinic acid synthesis.",
"   </p>",
"   <p>",
"    Deficiencies in the first four enzymes of the cycle (CPSI, OTC, ASS, or ASL) or in NAGS, the enzyme for co-factor in N-acetylglutamate production, result in accumulations of ammonia and the precursor metabolites [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20248/abstract/7\">",
"     7",
"    </a>",
"    ]. Primary mitochondrial disease secondarily may affect urea cycle activity, because CPSI, NAGS, and OTC are located in mitochondria. Hyperammonemia is rare or usually not severe in Arginase deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20248/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inheritance pattern of the UCDs is autosomal recessive, with the exception of OTC deficiency (which is X-linked). Thus, the recurrence risk for parents of an affected child (except OTC deficiency) is 25 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/13/7386?source=see_link\">",
"     \"Genetic and environmental causes of birth defects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because inheritance of OTC deficiency is X-linked, all female offspring of a male OTC-deficient parent will carry an OTC mutation, and 50 percent of all offspring (male and female) from a female OTC-deficient parent will carry the mutation. Hemizygous males usually are more severely affected than are heterozygous females. Approximately 10 percent of female carriers become symptomatic. The clinical severity in affected females depends upon the pattern of X-inactivation in the liver (also known as lyonization) and ranges from asymptomatic to almost as severe as in that of an affected male [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20248/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of affected patients present in early childhood, although those with a partial enzyme deficiency may become symptomatic later in childhood or as adults. Frequent vomiting and poor appetite with food refusal and protein aversion are common features in patients with UCD [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20248/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a large cohort of UCD patients from multiple centers (n = 260), only 34 percent presented during the neonatal period (&lt;30 days of age) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20248/abstract/13\">",
"     13",
"    </a>",
"    ]. Of the remaining patients, the first episode of hyperammonemia was reported at 31 days to 2 years of age in 18 percent, &gt;2 to 12 years of age in 28 percent, and over 12 years of age in 20 percent. The median age at presentation was two years (range 1 day to 53 years). The most common presenting symptoms in this cohort were neurologic (decreased level of consciousness, altered mental status, abnormal motor function, seizures) and gastrointestinal (vomiting, poor feeding, diarrhea, nausea, constipation).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Typical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe defects typically present in term newborns who appear well for the first 24 to 48 hours after birth. The infant becomes symptomatic after feeding has started because human milk or infant formula provides a protein load. Initial signs include somnolence, inability to maintain normal body temperature, and poor feeding, usually followed by vomiting, lethargy, and coma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20248/abstract/14,15\">",
"     14,15",
"    </a>",
"    ], a presentation that is identical to that of an infant with sepsis. However, the absence of risk factors for sepsis and a nondiagnostic sepsis evaluation should prompt consideration of a metabolic disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20248/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A common early sign in newborns with hyperammonemia is central hyperventilation leading to respiratory alkalosis. Hyperventilation is thought to result from cerebral edema caused by the accumulation of ammonia and other metabolites [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20248/abstract/17\">",
"     17",
"    </a>",
"    ]. Increasing cerebral edema also may result in abnormal posturing and progressive encephalopathy with hypoventilation and respiratory arrest. Approximately 50 percent of infants with severe hyperammonemia have seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20248/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Affected patients have a lifelong risk of metabolic decompensation with intercurrent hyperammonemia. Metabolic decompensation usually occurs during episodes of increased catabolism, such as infections (eg, gastroenteritis, otitis media), fasting, surgery, or trauma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Atypical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have partial enzyme deficiencies may have atypical presentations after the newborn period [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20248/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. This delayed presentation is most commonly seen in patients with partial OTC deficiency, such as female carriers, although it also occurs with partial activity of all urea cycle enzymes.",
"   </p>",
"   <p>",
"    Some patients with partial urea cycle enzyme deficiency present with chronic vomiting, developmental delay, a seizure disorder, sleep disorders, or psychiatric illness [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20248/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. Others may develop symptoms (eg, headache, anorexia, vomiting, lethargy, ataxia, behavioral abnormalities) following increased protein intake or during periods of catabolic stress (eg, viral illness, pregnancy) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20248/abstract/9,10,21\">",
"     9,10,21",
"    </a>",
"    ]. These patients tend to prefer vegetarian diets because dietary protein intake often is associated with headache. Still others present with laboratory abnormalities. There is emerging clinical evidence that UCDs may be complicated by hepatic dysfunction characterized by elevation of liver enzymes, coagulopathy, and histologic evidence of glycogenoses [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20248/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. The cause of this and other anecdotally reported morbidities may relate to deficiency of downstream intermediates, such as arginine, and dysregulation of nitric oxide synthesis or other arginine-derived intermediates [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20248/abstract/24-26\">",
"     24-26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with partial urea cycle enzyme deficiency, hyperammonemia may be chronic or occur only during metabolic decompensations associated with catabolic stress [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20248/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. The hyperammonemia is often less severe and the associated symptoms more subtle in patients with partial defects. It is important to consider a UCD in patients who have recurrent metabolic decompensations and to measure plasma ammonia concentration at the time of decompensation since ammonia may be normal during healthy periods [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20248/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Laboratory findings'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients with arginase deficiency typically present in later infancy to the preschool years. The most common physical findings are spasticity, especially of the lower extremities, dystonia, and ataxia. A diagnosis of cerebral palsy is often suspected. Other presenting symptoms are similar to those with partial urea cycle defects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     LABORATORY FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The laboratory hallmark of a UCD is an elevated plasma ammonia concentration (&gt;100 to 150",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"    However, as previously noted, ammonia may only be abnormal during periods of decompensation in patients with partial defects (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Atypical presentation'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Ammonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The plasma ammonia concentration can be measured in an arterial or venous blood sample. Measurement from a capillary blood sample is not reliable. Blood should be collected in chilled tubes with ammonia-free sodium",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    (green top) or EDTA (purple top), placed on ice, and delivered rapidly to the laboratory. Ammonia levels can be elevated falsely by hemolysis, delayed processing, and exposure to room temperature.",
"   </p>",
"   <p>",
"    Normal values for ammonia concentration are often higher in newborns than in older children or adults. In newborns, levels are affected by gestational and postnatal age. In one study, the mean plasma ammonia concentration of healthy term infants at birth was 45 &plusmn; 9",
"    <span class=\"nowrap\">",
"     micromol/L;",
"    </span>",
"    the upper limit of normal was 80 to 90",
"    <span class=\"nowrap\">",
"     micromol/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20248/abstract/29\">",
"     29",
"    </a>",
"    ]. Initial values in preterm infants less than 32 weeks' gestation were higher (mean 71 &plusmn; 26",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    but declined to term levels by seven days. Normal values in children older than one month and adults are less than 50 and 30",
"    <span class=\"nowrap\">",
"     micromol/L,",
"    </span>",
"    respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5559047\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Findings on neuroimaging are variable and depend upon the severity of the presentation and duration of hyperammonemia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20248/abstract/30\">",
"     30",
"    </a>",
"    ]. Imaging during acute presentation may show evidence of cerebral edema. Magnetic resonance imaging (MRI) of the brain in neonatal onset cases with prolonged hyperammonemia may show findings similar to that of hypoxic ischemic encephalopathy or heptic encephalopathy. As an example, neonatal OTC deficiency with prolonged hyperammonemia may lead to chronic changes including cortical atrophy, white matter cystic changes, and hypomyelination. Reversible white matter lesions may be seen even in milder late onset cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2417101\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ammonia levels should be measured in patients who present with typical clinical features of UCDs or who have a suggestive family history or an abnormal newborn screening test. If the plasma ammonia concentration is greater than 100 to 150",
"    <span class=\"nowrap\">",
"     micromol/L,",
"    </span>",
"    further testing is performed to establish a diagnosis. Mild elevations below this threshold should be interpreted in the context of the clinical course and followed to ensure resolution. Initial tests include arterial pH and carbon dioxide tension, serum lactate, serum glucose, serum electrolytes to calculate the anion gap, plasma amino acids, and urine organic acids and urine orotic acid. An elevated plasma ammonia concentration combined with normal blood glucose and anion gap strongly suggests a UCD. Additional plasma and urine should be frozen for future diagnostic tests. These samples may be useful to identify metabolic disorders in patients who have mild hyperammonemia and biochemical abnormalities during an acute illness and normal values when they appear well.",
"   </p>",
"   <p>",
"    Additional testing is used to identify the specific enzyme deficiency, including enzyme analysis and molecular genetic testing.",
"   </p>",
"   <p>",
"    Treatment should be initiated as soon as a UCD is suspected and should proceed concurrently with the diagnostic evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/49/19225?source=see_link&amp;anchor=H2#H2\">",
"     \"Urea cycle disorders: Management\", section on 'Initial management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Plasma amino acid/urine orotic acid analyses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quantitative plasma amino acid analysis is helpful to differentiate among UCDs (",
"    <a class=\"graphic graphic_algorithm graphicRef52126 \" href=\"UTD.htm?23/24/23950\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20248/abstract/15\">",
"     15",
"    </a>",
"    ]. Citrulline concentration is increased in ASS and ASL deficiencies; argininosuccinic acid is absent in the former and elevated in the latter.",
"   </p>",
"   <p>",
"    Citrulline is absent or low in CPSI, OTC, or NAGS deficiencies; arginine also is low, and glutamine is increased, in these disorders. If citrulline is absent, urine orotic acid measurement may differentiate OTC and CPS deficiencies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20248/abstract/14\">",
"     14",
"    </a>",
"    ]. Orotic acid can be increased to more than 1000",
"    <span class=\"nowrap\">",
"     micromol/mol",
"    </span>",
"    creatinine (normal, 1 to 11",
"    <span class=\"nowrap\">",
"     micromol/mol",
"    </span>",
"    creatinine) in the former and is low in the latter.",
"   </p>",
"   <p>",
"    Arginine is elevated three- to fourfold above the upper limit of normal in arginase deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20248/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Enzyme analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of a specific UCD is confirmed by enzyme analysis of tissue samples, as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Liver biopsy: CPSI, OTC, and NAGS deficiencies",
"     </li>",
"     <li>",
"      Fibroblasts from skin biopsy: ASS and ASL deficiencies",
"     </li>",
"     <li>",
"      Red blood cells: arginase deficiency",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Enzyme activity must be interpreted carefully. Measured enzyme activity does not always correlate with residual in vivo activity or with phenotypic severity, because most in vitro assays are performed with excess substrate. In addition, in the X-linked disorder OTC deficiency, the level of OTC activity measured in a liver biopsy may be normal in an affected female, depending upon the pattern of X-inactivation in the liver. Liver tissue, obtained by open or needle punch biopsy, can be used to test all enzymes affected in the urea cycle disorders when DNA testing is negative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Specialized testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Special techniques available in a research setting may be useful to detect abnormalities in patients with UCDs, especially those with partial enzyme deficiencies who have normal laboratory values during asymptomatic periods.",
"   </p>",
"   <p>",
"    The measurement of urinary excretion of orotic acid after administration of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/3/24629?source=see_link\">",
"     allopurinol",
"    </a>",
"    is one such technique that was used to detect women who were carriers of a mutant OTC allele [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20248/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. However, mild cases may have minimal elevations, and increased excretion may occur in mitochondrial disease, limiting the specificity of this test [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20248/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. With the wide availability of DNA testing, provocative testing (eg, with oral protein loads) should be avoided. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'DNA mutation analysis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The use of isotopes in vivo is another specialized technique that can be employed to assess altered urea cycle activity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20248/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. In one report, stable isotopes were used to measure rates of total body urea synthesis and nitrogen flux (which assesses urea cycle activity); these studies detected patients with complete and partial enzyme deficiencies and asymptomatic carriers, and results correlated with clinical severity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20248/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     DNA mutation analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;DNA sequencing-based mutation testing is clinically available for all genes of the urea cycle. DNA testing for OTC deficiency should be considered in patients with a suspected UCD, especially if the plasma amino acid pattern is not diagnostic, because OTC deficiency is the most common UCD. More than 150 mutations, most of which are single-base substitutions, have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20248/abstract/37\">",
"     37",
"    </a>",
"    ]. However, microdeletion of part, or all, of the OTC gene may lead to false negative results on DNA sequencing. Hence, array comparative genomic hybridization or chromosome microarray analysis to detect microdeletions of the gene is indicated when initial DNA sequencing is negative [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20248/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An increasingly effective alternative to targeted DNA mutation analysis is the application of next generation DNA sequencing for clinical whole exome analysis, which has the potential to identify variants in most if not all coding genes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20248/abstract/39\">",
"     39",
"    </a>",
"    ]. In so doing, all of the UCD genes as well as other gene variants that may cause hyperammonemia can be detected. Next generation DNA sequencing is increasingly replacing other methodologies in the initial diagnostic work up, because of the high sensitivity of this approach. However, sequencing may miss small single or multi-exon deletions, therefore array comparative genomic hybridization (aCGH) designed with single exon resolution should be performed in conjunction with DNA sequencing [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20248/abstract/38\">",
"     38",
"    </a>",
"    ]. Detection of a pathogenic mutation in an asymptomatic patient may preclude the need for a liver biopsy to confirm the diagnosis. Failure to detect a pathogenic mutation does not exclude the diagnosis, irrespective of the technology used for testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28536?source=see_link\">",
"     \"Cytogenetic and molecular genetic diagnostic tools\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Prenatal testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prenatal testing can be performed for all the UCDs by DNA analysis if the mutation is known [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20248/abstract/40\">",
"     40",
"    </a>",
"    ]; if an extended sibship is available, linkage analysis can be used, although it has limited sensitivity and specificity. The carrier status of both parents should be confirmed prior to prenatal DNA testing.",
"   </p>",
"   <p>",
"    If the molecular genetic studies are not informative, prenatal diagnosis may be available by biochemical testing. ASS and ASL enzyme activity can be measured directly in amniocytes and chorionic villus cells. Elevated citrulline and argininosuccinic acid can be measured in amniotic fluid. CPSI and OTC can be measured in fetal liver. The clinical phenotype of females with OTC deficiency cannot be predicted due to random inactivation of the X chromosome. Genetic counseling should be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2417193\">",
"    <span class=\"h2\">",
"     Newborn screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testing for UCDs and other inborn errors of metabolism by tandem mass spectrometry is now included in most newborn screening programs [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20248/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/2/2088?source=see_link\">",
"     \"Newborn screening\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of neonatal hyperammonemia includes a limited number of disorders, discussed below [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20248/abstract/14\">",
"     14",
"    </a>",
"    ]. Distinguishing features of UCDs include very high ammonia levels, which can be greater than 1000",
"    <span class=\"nowrap\">",
"     micromol/L,",
"    </span>",
"    in contrast to other etiologies in which ammonia rarely is higher than 200 to 300",
"    <span class=\"nowrap\">",
"     micromol/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20248/abstract/16\">",
"     16",
"    </a>",
"    ]. Other findings that suggest a UCD are normal blood glucose, normal anion gap, and respiratory alkalosis.",
"   </p>",
"   <p>",
"    Primary genetic causes of hyperammonemia include organic acidemias, fatty acid oxidation defects, and disorders of pyruvate metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20248/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperammonemia in organic acidemias results from inhibition of one of the urea cycle enzymes, most likely CPSI [",
"      <a class=\"abstract\" href=\"UTD.htm?19/49/20248/abstract/44\">",
"       44",
"      </a>",
"      ]. Patients with these disorders typically have metabolic acidosis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ketotic hypoglycemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27047?source=see_link\">",
"       \"Inborn errors of metabolism: Classification\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24489?source=see_link\">",
"       \"Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7914?source=see_link\">",
"       \"Organic acidemias\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/0/8201?source=see_link\">",
"       \"Approach to hypoglycemia in infants and children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fatty oxidation defects can cause hyperammonemia, but affected children typically have nonketotic hypoglycemia and present later in infancy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=see_link\">",
"       \"Inborn errors of metabolism: Metabolic emergencies\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21065?source=see_link\">",
"       \"Causes of metabolic myopathies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In disorders of pyruvate metabolism, lactic acidemia usually accompanies the elevated ammonia concentration. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=see_link\">",
"       \"Inborn errors of metabolism: Metabolic emergencies\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24489?source=see_link\">",
"       \"Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hyperornithinemia, hyperammonemia, homocitrullinemia (HHH syndrome, MIM #238970) is a rare cause of hyperammonemia. It is caused by impaired transport of ornithine, a basic amino acid, across the inner mitochondrial membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20248/abstract/45,46\">",
"     45,46",
"    </a>",
"    ], which leads to functional impairment of the urea cycle and elevated plasma concentrations of ornithine, ammonia, and citrulline (",
"    <a class=\"graphic graphic_figure graphicRef60652 \" href=\"UTD.htm?2/49/2832\">",
"     figure 1",
"    </a>",
"    ). Affected newborns typically present with lethargy, muscular hypotonia, and seizures. If untreated, death occurs within the first few days. The majority of survivors have pyramidal tract signs, with spastic paraparesis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20248/abstract/45,47\">",
"     45,47",
"    </a>",
"    ]. Most have myoclonic seizures, ataxia, and intellectual disability (mental retardation). A milder form of the disorder has been reported in adults, who become symptomatic following protein-rich meals [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20248/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Citrin deficiency or citrullinemia type II (neonatal onset MIM #605814, adult onset MIM #603471) is caused by defective aspartate transport between the mitochondria and the cytosol [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20248/abstract/48\">",
"     48",
"    </a>",
"    ]. This defective transport leads to insufficient substrate for ASS and secondary functional deficiency of ASS activity. Patients may present in the neonatal period with hepatitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intrahepatic cholestasis or they may present in adulthood with recurrent hyperammonemia and neuropsychiatric symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20248/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. Paradoxically, patients respond to a carbohydrate restricted high protein diet. Serum citrulline levels may be mildly elevated and threonine levels are elevated out of proportion of changes in serine levels.",
"   </p>",
"   <p>",
"    Transient hyperammonemia of the newborn (THAN) is an unusual cause of hyperammonemia. This condition may be distinguished from UCDs by its clinical features. In one report, patients with THAN had lower birth weight and gestational age, earlier presentation of hyperammonemia, and more respiratory distress than those with UCDs [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20248/abstract/51\">",
"     51",
"    </a>",
"    ]. Patients do not suffer from long-term risk of hyperammonemia and can tolerate normal diet without drug therapy.",
"   </p>",
"   <p>",
"    Causes of hyperammonemia that are not genetic include severe dehydration and liver failure. However, the plasma ammonia level typically is less than 100 to 200",
"    <span class=\"nowrap\">",
"     micromol/L",
"    </span>",
"    in dehydration and returns to normal with volume replacement. Hyperammonemia usually is seen late in the course of severe hepatocellular damage. Severe elevated hyperammonemia can also present with hepatic failure due to neonatal or perinatal herpes simplex virus infection, though the presentation is usually later in the first week of life or beyond [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20248/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/31/35321?source=see_link&amp;anchor=H9#H9\">",
"     \"Neonatal herpes simplex virus infection: Clinical features and diagnosis\", section on 'Disseminated disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The differential diagnosis in older children and adults who present with hyperammonemia includes hepatic encephalopathy in patients with advanced liver failure, valproic acid poisoning, severe dehydration, and gastrointestinal bacterial overgrowth. Liver function test abnormalities are seen in patients with hepatic encephalopathy and in most patients with valproic acid poisoning. Ammonia elevations are mild in patients with dehydration and bacterial overgrowth. Levels 100 to 150",
"    <span class=\"nowrap\">",
"     micromol/L",
"    </span>",
"    or greater should prompt a work up for a UCD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14506?source=see_link\">",
"     \"Hepatic encephalopathy: Pathogenesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/38/28264?source=see_link\">",
"     \"Valproic acid poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The urea cycle is the metabolic pathway that transforms nitrogen to urea for excretion from the body (",
"      <a class=\"graphic graphic_figure graphicRef60652 \" href=\"UTD.htm?2/49/2832\">",
"       figure 1",
"      </a>",
"      ). Deficiency of an enzyme in the pathway causes a urea cycle disorder (UCD). Prompt recognition and treatment are needed to improve outcome. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ornithine transcarbamylase deficiency is X-linked. The other UCDs are autosomal recessive. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of affected patients present in early childhood, although those with a partial enzyme deficiency may become symptomatic later in childhood or as adults. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In newborns, UCDs typically present at 24 to 48 hours of age. Clinical features include somnolence and poor feeding followed by lethargy, vomiting, and coma. Other features include central hyperventilation, hyperammonemia, and seizures. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Typical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with partial enzyme deficiency may present with chronic vomiting, developmental delay, seizure disorder, or psychiatric illness. Symptoms (eg, headache, vomiting, lethargy, ataxia) may be precipitated by increased protein intake or catabolic stress (eg, illness, pregnancy). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Atypical presentation'",
"      </a>",
"      above.) Arginase deficiency presents with more specific symptoms such as spastic diplegia, dystonia, or ataxia.",
"     </li>",
"     <li>",
"      The initial laboratory evaluation for suspected UCD should include arterial pH and carbon dioxide; serum ammonia, lactate, glucose, electrolytes, and amino acids; and urine organic acids and orotic acid. Elevated plasma ammonia concentration combined with normal blood glucose and normal anion gap strongly suggests a UCD. Additional testing is necessary to establish the diagnosis and identify the specific enzyme deficiency. Increasingly, DNA sequencing (targeted or whole exome-based approaches) in conjunction with array comparative genomic hybridization are being used as noninvasive alternatives to enzyme analysis of tissue samples. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Laboratory findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of neonatal hyperammonemia includes organic acidemias; fatty acid oxidation defects; disorders of pyruvate metabolism; hyperornithinemia, hyperammonemia, homocitrullinemia; transient hyperammonemia of the newborn; severe dehydration; and liver failure. Distinguishing features of UCD include the degree of elevation of plasma ammonia (typically &gt;1000",
"      <span class=\"nowrap\">",
"       micromol/L",
"      </span>",
"      for those disorders early in the cycle, ie, OTC deficiency, compared with 200 to 300",
"      <span class=\"nowrap\">",
"       micromol/L",
"      </span>",
"      for other genetic causes as well as for UCDs later in the cycle, ie, ASS and ASL deficiency), normal blood glucose, normal anion gap, and respiratory alkalosis. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Gene Reviews: Urea Cycle Disorders Overview. file://www.ncbi.nlm.nih.gov/books/NBK1217/ (Accessed on June 14, 2011).",
"    </li>",
"    <li>",
"     Gene Reviews: Citrullinemia type 1. file://www.ncbi.nlm.nih.gov/books/NBK1458/ (Accessed on June 14, 2011).",
"    </li>",
"    <li>",
"     Gene Reviews: Argininosuccinate lyase deficiency. file://www.ncbi.nlm.nih.gov/books/NBK51784/ (Accessed on June 14, 2011).",
"    </li>",
"    <li>",
"     Gene Reviews: Arginase deficiency. file://www.ncbi.nlm.nih.gov/books/NBK1159/ (Accessed on June 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20248/abstract/5\">",
"      Brusilow SW, Maestri NE. Urea cycle disorders: diagnosis, pathophysiology, and therapy. Adv Pediatr 1996; 43:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20248/abstract/6\">",
"      Moammar H, Cheriyan G, Mathew R, Al-Sannaa N. Incidence and patterns of inborn errors of metabolism in the Eastern Province of Saudi Arabia, 1983-2008. Ann Saudi Med 2010; 30:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20248/abstract/7\">",
"      Braissant O. Current concepts in the pathogenesis of urea cycle disorders. Mol Genet Metab 2010; 100 Suppl 1:S3.",
"     </a>",
"    </li>",
"    <li>",
"     GeneReviews: Arginase Deficiency. file://www.ncbi.nlm.nih.gov/books/NBK1159/ (Accessed on September 21, 2011).",
"    </li>",
"    <li>",
"     Brusilow SW, Horwich AL. Urea cycle enzymes. In: The metabolic and molecular bases of inherited disease, 8th ed, Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill, New York 2001. p.1909.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20248/abstract/10\">",
"      Leonard JV, Morris AA. Urea cycle disorders. Semin Neonatol 2002; 7:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20248/abstract/11\">",
"      Maestri NE, Brusilow SW, Clissold DB, Bassett SS. Long-term treatment of girls with ornithine transcarbamylase deficiency. N Engl J Med 1996; 335:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20248/abstract/12\">",
"      Gardeitchik T, Humphrey M, Nation J, Boneh A. Early clinical manifestations and eating patterns in patients with urea cycle disorders. J Pediatr 2012; 161:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20248/abstract/13\">",
"      Summar ML, Dobbelaere D, Brusilow S, Lee B. Diagnosis, symptoms, frequency and mortality of 260 patients with urea cycle disorders from a 21-year, multicentre study of acute hyperammonaemic episodes. Acta Paediatr 2008; 97:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20248/abstract/14\">",
"      Burton BK. Inborn errors of metabolism in infancy: a guide to diagnosis. Pediatrics 1998; 102:E69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20248/abstract/15\">",
"      Summar M. Current strategies for the management of neonatal urea cycle disorders. J Pediatr 2001; 138:S30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20248/abstract/16\">",
"      Maestri NE, Clissold D, Brusilow SW. Neonatal onset ornithine transcarbamylase deficiency: A retrospective analysis. J Pediatr 1999; 134:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20248/abstract/17\">",
"      Butterworth RF. Effects of hyperammonaemia on brain function. J Inherit Metab Dis 1998; 21 Suppl 1:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20248/abstract/18\">",
"      Maestri NE, Lord C, Glynn M, et al. The phenotype of ostensibly healthy women who are carriers for ornithine transcarbamylase deficiency. Medicine (Baltimore) 1998; 77:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20248/abstract/19\">",
"      Serrano M, Martins C, P&eacute;rez-Due&ntilde;as B, et al. Neuropsychiatric manifestations in late-onset urea cycle disorder patients. J Child Neurol 2010; 25:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20248/abstract/20\">",
"      Sedel F, Baumann N, Turpin JC, et al. Psychiatric manifestations revealing inborn errors of metabolism in adolescents and adults. J Inherit Metab Dis 2007; 30:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20248/abstract/21\">",
"      Houston B, Reiss KA, Merlo C. Healthy, but comatose. Am J Med 2011; 124:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20248/abstract/22\">",
"      Iorio R, Sepe A, Giannattasio A, et al. Hypertransaminasemia in childhood as a marker of genetic liver disorders. J Gastroenterol 2005; 40:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20248/abstract/23\">",
"      Miles L, Heubi JE, Bove KE. Hepatocyte glycogen accumulation in patients undergoing dietary management of urea cycle defects mimics storage disease. J Pediatr Gastroenterol Nutr 2005; 40:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20248/abstract/24\">",
"      Brunetti-Pierri N, Erez A, Shchelochkov O, et al. Systemic hypertension in two patients with ASL deficiency: a result of nitric oxide deficiency? Mol Genet Metab 2009; 98:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20248/abstract/25\">",
"      Erez A, Nagamani SC, Lee B. Argininosuccinate lyase deficiency-argininosuccinic aciduria and beyond. Am J Med Genet C Semin Med Genet 2011; 157:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20248/abstract/26\">",
"      Erez A, Nagamani SC, Shchelochkov OA, et al. Requirement of argininosuccinate lyase for systemic nitric oxide production. Nat Med 2011; 17:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20248/abstract/27\">",
"      Arn PH, Hauser ER, Thomas GH, et al. Hyperammonemia in women with a mutation at the ornithine carbamoyltransferase locus. A cause of postpartum coma. N Engl J Med 1990; 322:1652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20248/abstract/28\">",
"      Tuchman M, Yudkoff M. Blood levels of ammonia and nitrogen scavenging amino acids in patients with inherited hyperammonemia. Mol Genet Metab 1999; 66:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20248/abstract/29\">",
"      Usmani SS, Cavaliere T, Casatelli J, Harper RG. Plasma ammonia levels in very low birth weight preterm infants. J Pediatr 1993; 123:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20248/abstract/30\">",
"      Gropman A. Brain imaging in urea cycle disorders. Mol Genet Metab 2010; 100 Suppl 1:S20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20248/abstract/31\">",
"      Hauser ER, Finkelstein JE, Valle D, Brusilow SW. Allopurinol-induced orotidinuria. A test for mutations at the ornithine carbamoyltransferase locus in women. N Engl J Med 1990; 322:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20248/abstract/32\">",
"      Burlina AB, Ferrari V, Dionisi-Vici C, et al. Allopurinol challenge test in children. J Inherit Metab Dis 1992; 15:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20248/abstract/33\">",
"      Bonham JR, Guthrie P, Downing M, et al. The allopurinol load test lacks specificity for primary urea cycle defects but may indicate unrecognized mitochondrial disease. J Inherit Metab Dis 1999; 22:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20248/abstract/34\">",
"      Ahrens MJ, Berry SA, Whitley CB, et al. Clinical and biochemical heterogeneity in females of a large pedigree with ornithine transcarbamylase deficiency due to the R141Q mutation. Am J Med Genet 1996; 66:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20248/abstract/35\">",
"      Scaglia F, Zheng Q, O'Brien WE, et al. An integrated approach to the diagnosis and prospective management of partial ornithine transcarbamylase deficiency. Pediatrics 2002; 109:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20248/abstract/36\">",
"      Lee B, Yu H, Jahoor F, et al. In vivo urea cycle flux distinguishes and correlates with phenotypic severity in disorders of the urea cycle. Proc Natl Acad Sci U S A 2000; 97:8021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20248/abstract/37\">",
"      McCullough BA, Yudkoff M, Batshaw ML, et al. Genotype spectrum of ornithine transcarbamylase deficiency: correlation with the clinical and biochemical phenotype. Am J Med Genet 2000; 93:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20248/abstract/38\">",
"      Shchelochkov OA, Li FY, Geraghty MT, et al. High-frequency detection of deletions and variable rearrangements at the ornithine transcarbamylase (OTC) locus by oligonucleotide array CGH. Mol Genet Metab 2009; 96:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20248/abstract/39\">",
"      Bamshad MJ, Ng SB, Bigham AW, et al. Exome sequencing as a tool for Mendelian disease gene discovery. Nat Rev Genet 2011; 12:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20248/abstract/40\">",
"      Scaglia F, Brunetti-Pierri N, Kleppe S, et al. Clinical consequences of urea cycle enzyme deficiencies and potential links to arginine and nitric oxide metabolism. J Nutr 2004; 134:2775S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20248/abstract/41\">",
"      Wilcken B. Expanded newborn screening: reducing harm, assessing benefit. J Inherit Metab Dis 2010; 33:S205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20248/abstract/42\">",
"      Cavicchi C, Malvagia S, la Marca G, et al. Hypocitrullinemia in expanded newborn screening by LC-MS/MS is not a reliable marker for ornithine transcarbamylase deficiency. J Pharm Biomed Anal 2009; 49:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20248/abstract/43\">",
"      Huang HP, Chu KL, Chien YH, et al. Tandem mass neonatal screening in Taiwan--report from one center. J Formos Med Assoc 2006; 105:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20248/abstract/44\">",
"      Walser M, Stewart PM. Organic acidaemia and Hyperammonaemia: review. J Inherit Metab Dis 1981; 4:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20248/abstract/45\">",
"      Salvi S, Santorelli FM, Bertini E, et al. Clinical and molecular findings in hyperornithinemia-hyperammonemia-homocitrullinuria syndrome. Neurology 2001; 57:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20248/abstract/46\">",
"      Camacho JA, Obie C, Biery B, et al. Hyperornithinaemia-hyperammonaemia-homocitrullinuria syndrome is caused by mutations in a gene encoding a mitochondrial ornithine transporter. Nat Genet 1999; 22:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20248/abstract/47\">",
"      Lemay JF, Lambert MA, Mitchell GA, et al. Hyperammonemia-hyperornithinemia-homocitrullinuria syndrome: neurologic, ophthalmologic, and neuropsychologic examination of six patients. J Pediatr 1992; 121:725.",
"     </a>",
"    </li>",
"    <li>",
"     Gene Reviews: Citrin deficiency. file://www.ncbi.nlm.nih.gov/books/NBK1181/ (Accessed on June 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20248/abstract/49\">",
"      Tonini MC, Bignamini V, Mattioli M. Headache and neuropsychic disorders in the puerperium: a case report with suspected deficiency of urea cycle enzymes. Neurol Sci 2011; 32 Suppl 1:S157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20248/abstract/50\">",
"      Ko JM, Kim GH, Kim JH, et al. Six cases of citrin deficiency in Korea. Int J Mol Med 2007; 20:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20248/abstract/51\">",
"      Hudak ML, Jones MD Jr, Brusilow SW. Differentiation of transient hyperammonemia of the newborn and urea cycle enzyme defects by clinical presentation. J Pediatr 1985; 107:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20248/abstract/52\">",
"      Barnes PM, Wheldon DB, Eggerding C, et al. Hyperammonaemia and disseminated herpes simplex infection in the neonatal period. Lancet 1982; 1:1362.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2929 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-22FFA76FCA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_49_20248=[""].join("\n");
var outline_f19_49_20248=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Typical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Atypical presentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      LABORATORY FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Ammonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5559047\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2417101\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Plasma amino acid/urine orotic acid analyses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Enzyme analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Specialized testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DNA mutation analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Prenatal testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2417193\">",
"      Newborn screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/2929\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2929|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?23/24/23950\" title=\"algorithm 1\">",
"      Evaluation of hyperammonemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2929|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/49/2832\" title=\"figure 1\">",
"      Urea cycle",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/0/8201?source=related_link\">",
"      Approach to hypoglycemia in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21065?source=related_link\">",
"      Causes of metabolic myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28536?source=related_link\">",
"      Cytogenetic and molecular genetic diagnostic tools",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/13/7386?source=related_link\">",
"      Genetic and environmental causes of birth defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14506?source=related_link\">",
"      Hepatic encephalopathy: Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27047?source=related_link\">",
"      Inborn errors of metabolism: Classification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24489?source=related_link\">",
"      Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=related_link\">",
"      Inborn errors of metabolism: Metabolic emergencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/31/35321?source=related_link\">",
"      Neonatal herpes simplex virus infection: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/2/2088?source=related_link\">",
"      Newborn screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7914?source=related_link\">",
"      Organic acidemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/49/19225?source=related_link\">",
"      Urea cycle disorders: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/38/28264?source=related_link\">",
"      Valproic acid poisoning",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_49_20249="12 lead ECG CPVT";
var content_f19_49_20249=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76976&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76976&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    12-lead ECG in child with catecholaminergic polymorphic ventricular tachycardia (CPVT)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 350px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This is the ECG of a five-year-old with recurrent exertional syncope. The ECG demonstrates bidirectional VT. This child underwent genetic testing and was positive for the RyR2 mutation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_49_20249=[""].join("\n");
var outline_f19_49_20249=null;
var title_f19_49_20250="Treatment-related toxicity in men with testicular germ cell tumors";
var content_f19_49_20250=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment-related toxicity in men with testicular germ cell tumors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/49/20250/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/49/20250/contributors\">",
"     M Dror Michaelson, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/49/20250/contributors\">",
"     William K Oh, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/49/20250/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/49/20250/contributors\">",
"     Philip W Kantoff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/49/20250/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/49/20250/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/49/20250/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testicular cancers, 95 percent of which are germ cell tumors, are among the most curable solid neoplasms because of remarkable treatment advances beginning in the early 1970s. Prior to that time, testicular cancer accounted for 11 percent of all cancer deaths in men between the ages of 25 to 34, and the five-year survival rate was 64 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/1\">",
"     1",
"    </a>",
"    ]. There are about 350 deaths from testicular cancer annually in the United States, and the five-year survival rate is over 95 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Testicular germ-cell tumors (GCTs) are more sensitive to systemic chemotherapy than any other adult solid tumor. Conventional",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based regimens can cure up to 80 percent of patients with disseminated GCTs, including those with widespread visceral metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/4\">",
"     4",
"    </a>",
"    ]. An additional group of patients who relapse of have refractory disease can be cured by high-dose chemotherapy.",
"   </p>",
"   <p>",
"    As a result of these therapeutic successes, the majority of men with testicular GCTs are long-term survivors, and minimizing treatment-related toxicity from conventional and high dose chemotherapy has become a prime concern.",
"   </p>",
"   <p>",
"    Here, we will discuss the adverse effects of conventional doses of commonly used chemotherapeutic agents in testicular GCTs. The late effects of radiation therapy and general aspects of the management of patients with testicular germ cell tumors are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13432?source=see_link\">",
"     \"Overview of the treatment of testicular germ cell tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/2/22567?source=see_link\">",
"     \"Treatment of stage I seminoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HEMATOLOGIC",
"    </span>",
"    &nbsp;&mdash;&nbsp;For men with good risk testicular GCTs, standard dose chemotherapy (three cycles of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    [BEP, (",
"    <a class=\"graphic graphic_table graphicRef65516 \" href=\"UTD.htm?14/2/14382\">",
"     table 1",
"    </a>",
"    )], or four courses of etoposide and cisplatin [EP]) is generally well tolerated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=see_link&amp;anchor=H6#H6\">",
"     \"Initial risk-stratified treatment for advanced testicular germ cell tumors\", section on 'Good-risk'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Following each course of chemotherapy, the hematologic nadir will generally occur in week two or three, and may extend into the beginning of the subsequent cycle. A low white blood cell count at the beginning of a subsequent course of chemotherapy does not mandate dose reduction or treatment delay unless the previous cycle was a complicated and significant clinical event, such as febrile neutropenia.",
"   </p>",
"   <p>",
"    The concept that full doses should be administered at the scheduled time, regardless of the white blood cell count, is important; the curative potential of systemic chemotherapy may otherwise be compromised. While we do not use prophylactic hematopoietic growth factors (eg, granulocyte colony stimulating factors [G-CSF]) at the start of treatment, we recommend initiation of G-CSF in patients who develop low blood cell counts (on day 1 of the subsequent cycle) and those who had a complicated neutropenic event (eg, febrile neutropenia). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33945?source=see_link\">",
"     \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PULMONARY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Bleomycin toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most serious pulmonary toxicity associated with chemotherapy for testicular GCTs is the pneumonitis and pulmonary fibrosis attributed to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    . The incidence of bleomycin lung injury is cumulative, increasing significantly above 450 units. Predictive factors for the development of pulmonary toxicity include advanced age, prior or concurrent thoracic radiation therapy (RT), and renal dysfunction (particularly due to concomitant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ). This topic is discussed in detail elsewhere, and the discussion here will be limited to men treated for testicular cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12794?source=see_link\">",
"     \"Bleomycin-induced lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately one-half of all treatment related deaths in men treated with chemotherapy for testicular cancer are due to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    -induced pulmonary fibrosis, which is fatal in 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/4\">",
"     4",
"    </a>",
"    ]. The incidence of fatal bleomycin lung toxicity with four cycles of BEP is 1 to 2 percent, but is less than 1 percent when BEP is limited to three cycles [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/4-9\">",
"     4-9",
"    </a>",
"    ]. This low risk may be due to the fact that bleomycin is generally discontinued if patients show early signs of pneumonitis, although this is unproven.",
"   </p>",
"   <p>",
"    Signs and symptoms suggestive of early lung toxicity include a non-productive cough, exertional dyspnea and bibasilar crackles. Pulmonary nodules may be seen on chest imaging studies, although findings do not correlate with long-term damage [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/10\">",
"     10",
"    </a>",
"    ]. Nevertheless, it is standard practice to eliminate further",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    if radiographic changes are observed during treatment.",
"   </p>",
"   <p>",
"    Although pulmonary function tests (PFTs) are neither sensitive nor specific for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    lung toxicity, the best diagnostic tool for early detection is measurement of the diffusing capacity for carbon monoxide (DLCO) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/11\">",
"     11",
"    </a>",
"    ]. A decline in DLCO may be the earliest sign of lung injury. At most centers, baseline PFTs are established prior to chemotherapy, and then repeated at the start of each new cycle. Several authors recommend that bleomycin be discontinued if the DLCO falls by 40 percent, or to less than 60 percent of an individual's baseline value [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12794?source=see_link\">",
"     \"Bleomycin-induced lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite the potential for fatal pulmonary toxicity from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    , three or four courses of BEP or PVB chemotherapy in men with testicular cancer does not appear to lead to long-term impairment of pulmonary function [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/10,15,16\">",
"     10,15,16",
"    </a>",
"    ]. In one report, improvement in DLCO was noted in some patients as long as 43 months posttreatment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/15\">",
"     15",
"    </a>",
"    ]. However, these studies are limited by small sample size.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Late chemotherapy toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;High cumulative doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    chemotherapy may also be associated with late impairment of pulmonary function and restrictive lung disease.",
"   </p>",
"   <p>",
"    Pulmonary function and symptoms were analyzed with spirometry and a symptom questionnaire in a cohort of 1049 five-year survivors who had been treated in Norway between 1980 and 1994 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/17\">",
"     17",
"    </a>",
"    ]. Patients were divided into five treatment cohorts: orchiectomy only, radiation therapy,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    cumulative dose &le;850 mg, cisplatin cumulative dose &gt;850 mg, and cisplatin (any dose) with pulmonary surgery.",
"   </p>",
"   <p>",
"    At a median observation time of 11 years, the incidence of restrictive physiology was significantly increased in patients treated with high doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    or with cisplatin plus pulmonary surgery (18 and 17 percent, respectively, versus 7 percent in patients treated with orchiectomy alone). The observed changes in restrictive physiology were more closely correlated with cumulative cisplatin dose than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    dose, suggesting that cisplatin may also have long-term important effects on pulmonary function.",
"   </p>",
"   <p>",
"    Physicians caring for long-term survivors of testicular cancer should be aware of the potential for chemotherapy to adversely affect pulmonary function in a some patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Prevention of late pulmonary toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute respiratory failure from adult respiratory distress syndrome has been reported following general anesthesia in patients previously treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. It was suspected that exposure to high concentrations of oxygen could provoke latent pulmonary toxicity by increasing free radical formation in the lungs [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/5,18\">",
"     5,18",
"    </a>",
"    ]. However, a review of 77 patients undergoing major surgery following bleomycin-containing chemotherapy failed to demonstrate a correlation between perioperative oxygen restriction and either postoperative pulmonary morbidity or survival [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/20\">",
"     20",
"    </a>",
"    ]. These authors suggested that careful fluid management during surgery was more important than oxygen restriction.",
"   </p>",
"   <p>",
"    Nevertheless, patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    at any time in the past should not be exposed to high concentrations of inspired oxygen (either in the operating room or elsewhere) unless medically necessary to treat or prevent hypoxemia. When undergoing surgery, fluid balance must be carefully monitored and intravenous fluids and blood products administered judiciously. These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12794?source=see_link\">",
"     \"Bleomycin-induced lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     RENAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general aspects of renal toxicity associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    are discussed in detail elsewhere. Here we will focus on the available data in men receiving cisplatin-based regimens for testicular cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29833?source=see_link\">",
"     \"Cisplatin nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Renal insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite prophylactic measures such as large volume hydration and diuresis during drug administration, a reduction in the glomerular filtration rate (GFR) develops in 20 to 30 percent of patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    . The incidence and severity of renal failure increases with subsequent courses of therapy.",
"   </p>",
"   <p>",
"    Renal dysfunction appears to be partially reversible after treatment is discontinued. In one series of 34 men with testicular GCTs followed for over five years, GFR decreased by an average of 18 percent during treatment, recovered fully in ten men, and partially in eight [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/21\">",
"     21",
"    </a>",
"    ]. Up to 20 percent of treated patients have long-term reduction in creatinine clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/15,16,22,23\">",
"     15,16,22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Electrolyte disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persistent salt wasting is another manifestation of long-term renal toxicity. In two series, 20 to 30 percent of treated patients had evidence of persisting hypomagnesemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypophosphatemia an average of four years following chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. One report suggests an even higher proportion of patients with persistent hypomagnesemia, although the clinical significance of this laboratory finding is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Reducing nephrotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Modifications in the treatment regimen that may be associated with a reduced potential for nephrotoxicity include infusional rather than bolus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    , substitution of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , and the use of protective agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/42/678?source=see_link\">",
"     amifostine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     Carboplatin",
"    </a>",
"    is a less nephrotoxic drug than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    . However, four large randomized trials directly comparing carboplatin with cisplatin in men receiving combination chemotherapy for testicular GCTs have all demonstrated an inferior outcome with carboplatin [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. Thus, despite its more favorable toxicity profile, carboplatin should not be routinely used in the treatment of testicular GCTs. The use of renal protective agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/42/678?source=see_link\">",
"     amifostine",
"    </a>",
"    has not been tested in men receiving cisplatin for testicular GCTs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41738?source=see_link&amp;anchor=H6#H6\">",
"     \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\", section on 'Carboplatin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Hemolytic uremic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemolytic uremic syndrome is a rare complication of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , either alone, or with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    &nbsp;(see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=see_link\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     GONADAL EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fertility issues are of concern to men with testicular cancer for several reasons. Testicular GCTs are commonly associated with conditions (eg, cryptorchidism or testicular atrophy) with impaired Sertoli cell function and spermatogenesis. Furthermore, sperm motility is impaired in 50 percent of men with testicular cancer prior to therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/29\">",
"     29",
"    </a>",
"    ]. Azoospermia or severe oligospermia is present before any treatment in approximately 30 percent of men undergoing surgery for newly diagnosed testis cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/25/2457?source=see_link\">",
"     \"Epidemiology of and risk factors for testicular germ cell tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/24/13706?source=see_link&amp;anchor=H7#H7\">",
"     \"Effects of cytotoxic agents on gonadal function in adult men\", section on 'Testicular cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Spermatogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Orchiectomy may lead to further deterioration in spermatogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     Cisplatin",
"    </a>",
"    -based chemotherapy is associated with a dose-dependent impairment in infertility with defects in spermatogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/23,32-35\">",
"     23,32-35",
"    </a>",
"    ], but not sperm motility [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/36\">",
"     36",
"    </a>",
"    ]. The probability of recovery of spermatogenesis related to treatment intensity (both the number of cycles of chemotherapy, and the administered dose), the age of the patient at the time of treatment, and the severity of pretreatment oligospermia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/34,37,38\">",
"     34,37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At least one report documents no evidence of long-term fertility impairment following two courses of BEP chemotherapy administered in the adjuvant setting for stage I disease [",
"      <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, after three to four cycles of chemotherapy, most men develop a transient reduction in spermatogenesis that reaches a minimum 10 to 14 months after treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/30,34,37,40\">",
"       30,34,37,40",
"      </a>",
"      ]. Approximately three years later, sperm production recovers in approximately 70 percent of men [",
"      <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/32,34,35,38,41-43\">",
"       32,34,35,38,41-43",
"      </a>",
"      ]. In the largest series evaluating the time course of recovery of spermatogenesis, yearly sperm counts were assessed in 178 men after standard dose chemotherapy for testicular GCT [",
"      <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/34\">",
"       34",
"      </a>",
"      ]. Of the 89 men with normal pretreatment sperm counts, 64 percent were normal at one year. For all men, the probability of recovering some spermatogenesis was 48 and 80 percent at two and five years, respectively. At the same time points, the likelihood of achieving normal sperm counts was 22 and 58 percent, respectively. It should be noted that some men with persistent oligospermia following chemotherapy can successfully father children [",
"      <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/33\">",
"       33",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/24/13706?source=see_link\">",
"       \"Effects of cytotoxic agents on gonadal function in adult men\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3610?source=see_link\">",
"       \"Treatment of male infertility\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Higher chemotherapy doses (&gt;400",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      or &gt;850 mg total dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      ) is associated with a higher incidence of persistent azoospermia (approximately 50 percent in several studies [",
"      <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/32,38,44,45\">",
"       32,38,44,45",
"      </a>",
"      ]).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Hormonal changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum testosterone levels are usually normal before chemotherapy in men with testicular cancer, and are not consistently altered by standard chemotherapy doses [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/32,36,46-48\">",
"     32,36,46-48",
"    </a>",
"    ]. Long-term changes in gonadotropin levels, in contrast, are more prevalent. In one report of 63 men followed for a median of 42 months after chemotherapy, elevated follicle stimulating hormone (FSH) and luteinizing hormone (LH) levels were documented in 63 and 24 percent, respectively; despite this, only 10 percent had evidence of Leydig cell insufficiency and a subnormal testosterone level [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/49\">",
"     49",
"    </a>",
"    ]. Similar results have been noted by others [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/36,50,51\">",
"     36,50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of gonadal toxicity is significantly correlated with the cumulative platinum dose [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/32\">",
"     32",
"    </a>",
"    ]. Compared to men receiving two to four courses of chemotherapy, six cycles of PVB is associated with more prominent effects on gonadal function (and spermatogenesis, see above). High dose chemotherapy is associated with long-term reduction in testosterone levels and higher rates of persistent azoospermia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/32,45\">",
"     32,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other factors that may adversely affect reproductive capability in men with testicular cancer include RT and retroperitoneal lymph node dissection (RPLND). Although older RPLND techniques caused ejaculatory dysfunction in nearly all patients, improvements in surgical technique have reduced the frequency of this complication; furthermore, fewer men undergo RPLND than in the past. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/3/9272?source=see_link\">",
"     \"Retroperitoneal lymph node dissection in testicular germ cell tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/2/22567?source=see_link&amp;anchor=H261198349#H261198349\">",
"     \"Treatment of stage I seminoma\", section on 'Adjuvant radiation therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of these issues, sperm banking is often recommended prior to initiating chemotherapy in young patients who may desire future fertility [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     CARDIOVASCULAR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accumulating evidence suggests that vascular toxicity is one of the most important late consequences of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based chemotherapy in the treatment of men with advanced testicular GCTs. The major cardiovascular issues that have been studied include dyslipidemia, hypertension, early atherosclerosis and coronary artery disease (CAD), Raynaud's phenomenon, and thromboembolic events.",
"   </p>",
"   <p>",
"    Long-term survivors of testicular cancer have an increased risk of developing both an unfavorable cardiovascular risk profile and cardiovascular disease following treatment with chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/53-56\">",
"     53-56",
"    </a>",
"    ]. Although the observed increase in toxicity may be due in part to these risk factors, other mechanisms, including direct vascular toxicity from the chemotherapy, may have a role [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/55,57,58\">",
"     55,57,58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An increased risk of cardiovascular disease has also been associated with radiation therapy in patients who receive both subdiaphragmatic and mediastinal radiation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/54,56\">",
"     54,56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34137?source=see_link\">",
"     \"Cardiotoxicity of radiation therapy for malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to the late consequences of chemotherapy, there is a small risk of early cardiovascular events, including myocardial infarction, stroke, and arterial thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. A multi-institution survey in Germany identified 25 such cases over a 12-year period, including 20 myocardial infarctions during or within six weeks after chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/60\">",
"     60",
"    </a>",
"    ]. The estimated incidence of such events was 0.3 percent.",
"   </p>",
"   <p>",
"    The pathophysiologic mechanisms underlying cardiovascular toxicity have not been extensively studied [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/59,61\">",
"     59,61",
"    </a>",
"    ]. While one study showed increased plasma renin and aldosterone activity following chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/61\">",
"     61",
"    </a>",
"    ], others have found no correlation between hypertension and reduced renal function or alterations in the renin-angiotensin-aldosterone system. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7337?source=see_link\">",
"     \"Overview of hypertension in acute and chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13720?source=see_link\">",
"     \"Chapter 2B: Renin-angiotensin system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     The metabolic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The metabolic syndrome (hypertension, dyslipidemia, insulin resistance, and obesity) has been reported in many studies of survivors for testicular cancer and may be associated with the cumulative dose of chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/62-66\">",
"     62-66",
"    </a>",
"    ]. This syndrome has been recognized as a proinflammatory, prothrombotic state that is associated with elevated levels of C-reactive protein, interleukin (IL)-6, and plasminogen activator inhibitor-1, increasing the risk for subsequent cardiovascular disease and type 2 diabetes. The etiology of the metabolic syndrome in testicular cancer survivors is unclear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=see_link\">",
"     \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Hyperlipidemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Men receiving chemotherapy for testicular cancer have alterations in their lipid profiles, possibly due to endocrinologic disturbances [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/50,67,68\">",
"     50,67,68",
"    </a>",
"    ]. In one series with a detailed lipid analysis, men previously treated with chemotherapy had a higher mean total cholesterol, ratio of total to HDL cholesterol, and triglycerides compared to those undergoing orchiectomy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/69\">",
"     69",
"    </a>",
"    ]. The previously described study with ten-year follow-up after chemotherapy documented a mean increase in total cholesterol from 181",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    pretreatment to 233",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    posttreatment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/70\">",
"     70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33241?source=see_link\">",
"     \"Screening guidelines for dyslipidemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemotherapy can increase the blood pressure and cause hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/21,50,56,68-71\">",
"     21,50,56,68-71",
"    </a>",
"    ]. This was illustrated by a series that compared 500 long-term survivors treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -containing chemotherapy with those treated with surgery alone (n = 242), radiotherapy (n = 547), or a control group of healthy males (n = 2847); those treated with chemotherapy had a higher prevalence of hypertension than surgically treated patients or controls [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/71\">",
"     71",
"    </a>",
"    ]. The incidence of hypertension was higher in those patients who had received the highest cumulative doses of cisplatin (&gt;850 mg).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Myocardial ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several large series have shown that there is an increased risk of ischemic events in long-term survivors of testicular GCTs [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/53,55,56,71,72\">",
"     53,55,56,71,72",
"    </a>",
"    ]. In one report, the incidence of ischemic heart disease in 2512 long-term survivors in the Netherlands was compared to that of the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/53\">",
"     53",
"    </a>",
"    ]. The standardized incidence ratio for angina or myocardial infarction was 1.17 (95% CI, 1.04 to 1.31). Factors associated with an increased risk of myocardial infarction included mediastinal irradiation and the use of a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -containing chemotherapy regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Raynaud's phenomenon",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Raynaud's phenomenon (RP) resulting from chemotherapy for GCTs was first described in 1977 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/73\">",
"     73",
"    </a>",
"    ]. Both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    have been implicated as causes of secondary RP. The incidence is approximately 20 to 40 percent, depending upon drug dose and regimen, methods of drug administration, electrolyte levels, and individual risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/70,74,75\">",
"     70,74,75",
"    </a>",
"    ]. Although some series have suggested a correlation between hypomagnesemia and RP [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/76\">",
"     76",
"    </a>",
"    ], others have failed to confirm this association [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/21,70\">",
"     21,70",
"    </a>",
"    ]. In one report, hypertension, but not tobacco use increased the risk of developing RP in association with chemotherapy for testicular cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/70\">",
"     70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/48/6921?source=see_link&amp;anchor=H11#H11\">",
"     \"Clinical manifestations and diagnosis of the Raynaud phenomenon\", section on 'Secondary RP'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Symptoms may begin at any time during treatment and up to three years after the completion of chemotherapy. The particular chemotherapy regimen is of some importance. As an example, in one cohort of 60 men with testicular GCT receiving chemotherapy, 37 percent developed RP within one year, and the incidence was higher with PVB compared to VB without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (41 versus 21 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/76\">",
"     76",
"    </a>",
"    ]. In a second series of 90 patients, the incidence of RP was significantly higher in men receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    (PVB) compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    (PEB, 57 versus 25 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/70\">",
"     70",
"    </a>",
"    ]. Furthermore, continuous infusion",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    was associated with a lower incidence than bolus infusion bleomycin [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/70\">",
"     70",
"    </a>",
"    ]. There may be a role for calcium channel blockers in treatment of chemotherapy-induced RP [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/77\">",
"     77",
"    </a>",
"    ]. The treatment of RP is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/30/28138?source=see_link\">",
"     \"Treatment of the Raynaud phenomenon resistant to initial therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Thromboembolic events",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of thromboembolic events, mainly deep vein thrombosis and pulmonary embolism, is increased in men who are undergoing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based therapy for GCTs [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/78-81\">",
"     78-81",
"    </a>",
"    ]. At least one report suggests that a high body surface area (&gt;1.9 m",
"    <sup>",
"     2",
"    </sup>",
"    ) and elevated serum levels of lactate dehydrogenase (LDH) predispose to thromboembolic events [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/81\">",
"     81",
"    </a>",
"    ]. The risk of a thromboembolic event during therapy was 4 and 26 percent for men with no risk factors and those with at least one risk factor, respectively.",
"   </p>",
"   <p>",
"    Rare arterial vascular events following treatment have been reported as well. However, the small number of cases, and the limited duration of follow-up, have prevented confirmation of this association [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/69,82\">",
"     69,82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Changes in body metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been hypothesized that long-term cardiovascular side effects may be a result of metabolic changes rather than the chemotherapy itself. Some data show that survivors of chemotherapy-treated testicular cancer have a disproportionate annual increase in body mass index (BMI) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/63,68,71\">",
"     63,68,71",
"    </a>",
"    ]. However, others suggest that this is related to hormonal and age-related changes rather than to chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/83\">",
"     83",
"    </a>",
"    ]. In at least one report of long-term survivors, men undergoing orchiectomy alone for testicular cancer had similar increases in BMI as those who also received chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients cured of testicular cancer also have a greater than average level of physical activity, likely as a psychological consequence of their experience with cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Men who have been treated for testicular GCT require long-term follow-up that includes a focus on the potential for cardiovascular complications and interventions to reduce the risk of myocardial ischemia. Current guidelines recommend screening for hypertension every two years in individuals over the age of 20, and checking a lipid profile every five years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/45/9943?source=see_link\">",
"     \"Posttreatment follow-up for men with testicular germ cell tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=see_link\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     NEUROLOGIC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic toxicity is common during treatment. The main culprit is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , which causes both a distal, mainly sensory neuropathy with motor sparing, and ototoxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     Cisplatin",
"    </a>",
"    causes an axonal neuropathy that affects predominantly large myelinated sensory fibers. The primary site of damage is the dorsal root ganglion, but the peripheral nerve is also affected. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37242?source=see_link&amp;anchor=H2#H2\">",
"     \"Neurologic complications of platinum-based chemotherapy\", section on 'Cisplatin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most men experience some degree of neuropathy during chemotherapy for testicular cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/85,86\">",
"     85,86",
"    </a>",
"    ], and further deterioration in the three months following chemotherapy may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/87\">",
"     87",
"    </a>",
"    ]. Patients typically complain of paresthesias, dysesthesias, and disturbances in vibratory and position sense that begins in the toes and fingers and spreads proximally. Patients with mild neuropathy can continue to receive full doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ; however, once the neuropathy becomes more severe and begins to interfere with neurologic function, the clinician must weigh the risk of potentially disabling neurotoxicity against the benefit of continued treatment.",
"   </p>",
"   <p>",
"    The neuropathy eventually improves in most patients, although recovery is often incomplete [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/74\">",
"     74",
"    </a>",
"    ]. Persistent symptomatic sensory neuropathy is reported in approximately 20 to 30 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. Prophylactic strategies, such as pretreatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/42/678?source=see_link\">",
"     amifostine",
"    </a>",
"    , have been partially successful in delaying or preventing the development of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -induced neuropathy, but use of this agent is not routine in the treatment of testis cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37242?source=see_link&amp;anchor=H2#H2\">",
"     \"Neurologic complications of platinum-based chemotherapy\", section on 'Cisplatin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     Vinblastine",
"    </a>",
"    also is a neurotoxin, and replacement of vinblastine with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    has reduced the incidence of treatment-related neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43530?source=see_link&amp;anchor=H22#H22\">",
"     \"Neurologic complications of non-platinum cancer chemotherapy\", section on 'Other vinca alkaloids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Ototoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another common",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -related neurologic effect is ototoxicity, manifested by high-frequency sensorineural hearing loss and tinnitus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37242?source=see_link&amp;anchor=H2#H2\">",
"     \"Neurologic complications of platinum-based chemotherapy\", section on 'Cisplatin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although some degree of hearing loss is reported by about one-half of patients undergoing chemotherapy for testicular cancer, audiometric hearing loss can be detected in almost 90 percent. The risk of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -induced ototoxicity is both dose and schedule-dependent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/88\">",
"     88",
"    </a>",
"    ]. Other risk factors include the concurrent administration of other ototoxins, and exposure to loud noise (including loud music) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. The majority of patients have complete resolution of ototoxicity with cessation of therapy; however, tinnitus or hearing impairment persists in approximately 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/50,74,88\">",
"     50,74,88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SECOND MALIGNANCIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most dreaded complication of therapy for testicular cancer is the development of a secondary malignancy. Second primary cancers have emerged as a leading cause of death among testicular cancer survivors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Solid tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of developing or dying from a second malignancy is two to three times greater in survivors of testicular cancer than in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/54,72,90-92\">",
"     54,72,90-92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The largest study to date included 40,576 testicular cancer survivors from 14 population-based tumor registries in Europe and North America, more than 7800 followed for 20 years, and 2065 followed for 30 years [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/90\">",
"     90",
"    </a>",
"    ]. Among the most important findings were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 10-year survivors diagnosed with testicular cancer at an average age of 35 years, the relative risk (RR) of developing a solid tumor relative to expected rates in men from the same registration area of similar age was 1.9 (95% CI 1.8 to 2.1). Risk remained significantly elevated for at least 35 years. The cumulative risk of developing a solid cancer by age 75 (ie, 40 years after treatment) for men with seminoma and nonseminoma histology was 36 and 31 percent, respectively, compared to 23 percent for the general population.",
"     </li>",
"     <li>",
"      Cancer of the lung (RR 1.5, 95% CI 1.2-1.7), colon (RR 2.0, 95% CI 1.7-2.5), bladder (RR 2.7, 95% CI 2.2-3.1), pancreas (RR 3.6, 95% CI2.8-4.6) and stomach (RR 4.0, 95% CI 3.2-4.8) accounted for almost 60 percent of the total excess number of solid tumors. In contrast to other studies, this study found that risks were also elevated for mesothelioma (RR 3.4, 95% CI 1.7 to 5.9) and esophageal cancer (RR 1.7, 95% CI 1.0 to 2.6). Among men receiving RT alone, sites in typical infradiaphragmatic radiotherapy fields (ie, bladder, stomach, pancreas, kidney) accounted for 64 percent of the excess cancers.",
"     </li>",
"     <li>",
"      The relative risk and excess absolute risk of a second cancer decreased with increasing age at diagnosis of testicular cancer. As an example, a man diagnosed with seminoma at age 20 would have a 47 percent predicted cumulative risk of a solid cancer by age 75; the corresponding rates for a man diagnosed at age 35 or 50 would be 36 and 28 percent, respectively.",
"     </li>",
"     <li>",
"      Overall patterns were similar for seminoma and nonseminoma, although lower risks were observed for nonseminoma patients treated after 1975.",
"     </li>",
"     <li>",
"      An increased risk of second solid cancers was seen among men treated with RT alone (RR 2.0, 95% CI 1.9 to 2.2), chemotherapy alone (RR 1.8, 95% CI 1.3 to 2.5) and with both modalities (RR 2.9, 95% CI 1.9 to 4.2).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Men with testicular GCT who undergo chemotherapy are also at an increased risk of developing leukemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39480?source=see_link\">",
"     \"Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The contribution of radiotherapy to risk has not been well characterized. Contemporary studies evaluating large numbers of treated men suggest that the incidence of secondary leukemia is low, &lt;0.5 percent, following a typical three- or four-cycle course of BEP, in which the cumulative",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    dose is &lt;2000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/90,93\">",
"     90,93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, prolonged use of high doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    is associated with a significantly higher risk of secondary myelogenous leukemias that are highly refractory to treatment. Epidophyllotoxin-induced leukemia is characterized by an onset two to three years following treatment and a hallmark chromosomal translocation involving the long arm of chromosome 11 (11q23) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/94\">",
"     94",
"    </a>",
"    ]. The risk of secondary leukemia may be as high as 5 percent in those receiving more than 2000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    (representing a 336-fold increase in the likelihood of leukemia) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/93,95-101\">",
"     93,95-101",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/42/39594?source=see_link&amp;anchor=H16#H16\">",
"     \"Cytogenetics in acute myeloid leukemia\", section on 'Following DNA topoisomerase II inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Combination chemotherapy cures a substantial number of men with advanced testicular GCT, including 90 percent of those with good-risk advanced disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=see_link\">",
"     \"Initial risk-stratified treatment for advanced testicular germ cell tumors\"",
"    </a>",
"    .) Risk-benefit analyses have concluded that the benefit of standard dose chemotherapy regimens in advanced GCT outweighs the risk of treatment-related leukemia. In one review of 18,000 testis cancer survivors, it was estimated that following standard dose chemotherapy, 16 cases of secondary leukemia would be expected in 10,000 treated men.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Treatment outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concerns exist that second malignancies in testicular cancer survivors might have a worse prognosis, due to either late treatment effects preventing effective therapy or altered biology caused by the original treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/102\">",
"     102",
"    </a>",
"    ]. Despite these issues, testicular cancer survivors who develop a second primary malignancy appear to have a similar outcome to comparable patients with a first primary malignancy.",
"   </p>",
"   <p>",
"    In a study of 29,356 men with testicular cancer from the Surveillance, Epidemiology and End Results (SEER) database, 621 cases were identified with a second cancer of known stage [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/102\">",
"     102",
"    </a>",
"    ]. These were compared with 12,420 men with a first primary malignancy; patients were matched for primary site, stage at diagnosis, year of diagnosis, and age. There was no significant increase in either cancer-related mortality (hazard ratio [HR] 1.05, 95% CI 0.90-1.23) or all cause mortality (HR 1.09, 95% CI 0.96-1.23) compared to the control population.",
"   </p>",
"   <p>",
"    The one exception was testicular cancer patients treated between 1973 and 1979, a period when substantially higher doses of RT were used, and RT often included treatment to the thorax. In that subset, there was a significant increase in both cancer-related mortality (HR 1.44, 95% CI 1.13-1.83) and overall mortality (HR 1.65, 95% CI 1.12-2.42).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     NONCANCER MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemotherapy-related toxicity is associated with a small, but statistically significant, increase in late noncancer mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/103-105\">",
"     103-105",
"    </a>",
"    ]. This was illustrated by a multicenter tumor registry study involving almost 39,000 testicular cancer patients, in which noncancer deaths exceeded that expected in the general population by 6 percent (standardized mortality ratio [SMR] 1.06, 95% CI 1.02-1.10) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/49/20250/abstract/103\">",
"     103",
"    </a>",
"    ]. Although the magnitude of this risk is small, attention to risk factors for cardiovascular is important. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Cardiovascular'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testicular germ cell tumors (GCTs) are remarkably sensitive to multiple chemotherapy regimens and are curable in approximately 95 percent of cases with currently available treatment modalities. As a result of these therapeutic successes, the majority of men with testicular GCTs are long-term survivors. Thus minimizing the late effects of treatment has become a primary concern.",
"   </p>",
"   <p>",
"    Late toxicities associated with treatment of GCTs can affect multiple systems:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary -",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       Bleomycin",
"      </a>",
"      can cause pneumonitis and pulmonary fibrosis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pulmonary'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12794?source=see_link\">",
"       \"Bleomycin-induced lung injury\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Renal &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       Cisplatin",
"      </a>",
"      is an integral component of the most effective chemotherapy regimens. Cisplatin is nephrotoxic and can be associated with a decrease in the glomerular filtration rate. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Renal'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29833?source=see_link\">",
"       \"Cisplatin nephrotoxicity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fertility &mdash; Testicular GCTs are often associated with impaired spermatogenesis. Treatment (orchiectomy, chemotherapy, radiation therapy) can further impair spermatogenesis. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Gonadal effects'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/24/13706?source=see_link\">",
"       \"Effects of cytotoxic agents on gonadal function in adult men\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cardiovascular &mdash; Vascular toxicity is one of the most important late consequences of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based chemotherapy regimens. Major cardiovascular issues include dyslipidemia, hypertension, early atherosclerosis and coronary artery disease (CAD), Raynaud phenomenon, and thromboembolic events. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Cardiovascular'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neurotoxicity &mdash; Neurologic toxicity is common during treatment. This is primarily associated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      , which typically causes sensory neuropathy with motor sparing and ototoxicity, and with older regimens incorporating",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Neurologic'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37242?source=see_link\">",
"       \"Neurologic complications of platinum-based chemotherapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Second malignancies &mdash; Both chemotherapy and radiotherapy have been associated with late secondary malignancies, which are more common in testicular GCT survivors than in the general population. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Second malignancies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/1\">",
"      Einhorn LH. Treatment of testicular cancer: a new and improved model. J Clin Oncol 1990; 8:1777.",
"     </a>",
"    </li>",
"    <li>",
"     Ries LA, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review, 1975-2001, National Cancer Institute, Bethesda, MD, 2004 file://seer.cancer.gov/csr/1975_2007/index.html (Accessed on April 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/3\">",
"      Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/4\">",
"      Williams SD, Birch R, Einhorn LH, et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987; 316:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/5\">",
"      Jules-Elysee K, White DA. Bleomycin-induced pulmonary toxicity. Clin Chest Med 1990; 11:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/6\">",
"      de Wit R, Stoter G, Kaye SB, et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 1997; 15:1837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/7\">",
"      Loehrer PJ Sr, Johnson D, Elson P, et al. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol 1995; 13:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/8\">",
"      Levi JA, Raghavan D, Harvey V, et al. The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma. Australasian Germ Cell Trial Group. J Clin Oncol 1993; 11:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/9\">",
"      de Wit R, Roberts JT, Wilkinson PM, et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 2001; 19:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/10\">",
"      Lehne G, Johansen B, Foss&aring; SD. Long-term follow-up of pulmonary function in patients cured from testicular cancer with combination chemotherapy including bleomycin. Br J Cancer 1993; 68:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/11\">",
"      McKeage MJ, Evans BD, Atkinson C, et al. Carbon monoxide diffusing capacity is a poor predictor of clinically significant bleomycin lung. New Zealand Clinical Oncology Group. J Clin Oncol 1990; 8:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/12\">",
"      Comis RL. Detecting bleomycin pulmonary toxicity: a continued conundrum. J Clin Oncol 1990; 8:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/13\">",
"      Hirsch A, Vander Els N, Straus DJ, et al. Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease. J Clin Oncol 1996; 14:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/14\">",
"      Jensen JL, Goel R, Venner PM. The effect of corticosteroid administration on bleomycin lung toxicity. Cancer 1990; 65:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/15\">",
"      Petersen PM, Hansen SW. The course of long-term toxicity in patients treated with cisplatin-based chemotherapy for non-seminomatous germ-cell cancer. Ann Oncol 1999; 10:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/16\">",
"      Osanto S, Bukman A, Van Hoek F, et al. Long-term effects of chemotherapy in patients with testicular cancer. J Clin Oncol 1992; 10:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/17\">",
"      Haugnes HS, Aass N, Foss&aring; SD, et al. Pulmonary function in long-term survivors of testicular cancer. J Clin Oncol 2009; 27:2779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/18\">",
"      Goldiner PL, Carlon GC, Cvitkovic E, et al. Factors influencing postoperative morbidity and mortality in patients treated with bleomycin. Br Med J 1978; 1:1664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/19\">",
"      Nygaard K, Smith-Erichsen N, Hatlevoll R, Refsum SB. Pulmonary complications after bleomycin, irradiation and surgery for esophageal cancer. Cancer 1978; 41:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/20\">",
"      Donat SM, Levy DA. Bleomycin associated pulmonary toxicity: is perioperative oxygen restriction necessary? J Urol 1998; 160:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/21\">",
"      Hansen SW, Groth S, Daugaard G, et al. Long-term effects on renal function and blood pressure of treatment with cisplatin, vinblastine, and bleomycin in patients with germ cell cancer. J Clin Oncol 1988; 6:1728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/22\">",
"      Boyer M, Raghavan D, Harris PJ, et al. Lack of late toxicity in patients treated with cisplatin-containing combination chemotherapy for metastatic testicular cancer. J Clin Oncol 1990; 8:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/23\">",
"      Bokemeyer C, Berger CC, Kuczyk MA, Schmoll HJ. Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol 1996; 14:2923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/24\">",
"      Vogelzang NJ, Torkelson JL, Kennedy BJ. Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin. Cancer 1985; 56:2765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/25\">",
"      Tjulandin SA, Garin AM, Mescheryakov AA, et al. Cisplatin-etoposide and carboplatin-etoposide induction chemotherapy for good-risk patients with germ cell tumors. Ann Oncol 1993; 4:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/26\">",
"      Bajorin DF, Sarosdy MF, Pfister DG, et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol 1993; 11:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/27\">",
"      Bokemeyer C, K&ouml;hrmann O, Tischler J, et al. A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors. Ann Oncol 1996; 7:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/28\">",
"      Horwich A, Sleijfer DT, Foss&aring; SD, et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 1997; 15:1844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/29\">",
"      Foss&aring; SD, Abyholm T, Aakvaag A. Spermatogenesis and hormonal status after orchiectomy for cancer and before supplementary treatment. Eur Urol 1984; 10:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/30\">",
"      Petersen PM, Skakkebaek NE, R&oslash;rth M, Giwercman A. Semen quality and reproductive hormones before and after orchiectomy in men with testicular cancer. J Urol 1999; 161:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/31\">",
"      Sibert L, Rives N, Rey D, et al. Semen cryopreservation after orchidectomy in men with testicular cancer. BJU Int 1999; 84:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/32\">",
"      Petersen PM, Hansen SW, Giwercman A, et al. Dose-dependent impairment of testicular function in patients treated with cisplatin-based chemotherapy for germ cell cancer. Ann Oncol 1994; 5:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/33\">",
"      Stephenson WT, Poirier SM, Rubin L, Einhorn LH. Evaluation of reproductive capacity in germ cell tumor patients following treatment with cisplatin, etoposide, and bleomycin. J Clin Oncol 1995; 13:2278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/34\">",
"      Lampe H, Horwich A, Norman A, et al. Fertility after chemotherapy for testicular germ cell cancers. J Clin Oncol 1997; 15:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/35\">",
"      Nijman JM, Schraffordt Koops H, Kremer J, et al. Fertility and hormonal function in patients with a nonseminomatous tumor of the testis. Arch Androl 1985; 14:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/36\">",
"      Hansen SW, Berthelsen JG, von der Maase H. Long-term fertility and Leydig cell function in patients treated for germ cell cancer with cisplatin, vinblastine, and bleomycin versus surveillance. J Clin Oncol 1990; 8:1695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/37\">",
"      Aass N, Foss&aring; SD, Theodorsen L, Norman N. Prediction of long-term gonadal toxicity after standard treatment for testicular cancer. Eur J Cancer 1991; 27:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/38\">",
"      Bryd&oslash;y M, Foss&aring; SD, Klepp O, et al. Paternity following treatment for testicular cancer. J Natl Cancer Inst 2005; 97:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/39\">",
"      Cullen MH, Stenning SP, Parkinson MC, et al. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J Clin Oncol 1996; 14:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/40\">",
"      Foss&aring; SD, Theodorsen L, Norman N, Aabyholm T. Recovery of impaired pretreatment spermatogenesis in testicular cancer. Fertil Steril 1990; 54:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/41\">",
"      Hansen PV, Hansen SW. Gonadal function in men with testicular germ cell cancer: the influence of cisplatin-based chemotherapy. Eur Urol 1993; 23:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/42\">",
"      Pont J, Albrecht W, Postner G, et al. Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J Clin Oncol 1996; 14:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/43\">",
"      Huyghe E, Matsuda T, Daudin M, et al. Fertility after testicular cancer treatments: results of a large multicenter study. Cancer 2004; 100:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/44\">",
"      Ishikawa T, Kamidono S, Fujisawa M. Fertility after high-dose chemotherapy for testicular cancer. Urology 2004; 63:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/45\">",
"      Gerl A, M&uuml;hlbayer D, Hansmann G, et al. The impact of chemotherapy on Leydig cell function in long term survivors of germ cell tumors. Cancer 2001; 91:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/46\">",
"      Leitner SP, Bosl GJ, Bajorunas D. Gonadal dysfunction in patients treated for metastatic germ-cell tumors. J Clin Oncol 1986; 4:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/47\">",
"      Howell SJ, Radford JA, Ryder WD, Shalet SM. Testicular function after cytotoxic chemotherapy: evidence of Leydig cell insufficiency. J Clin Oncol 1999; 17:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/48\">",
"      Lackner J, Schatzl G, Koller A, et al. Treatment of testicular cancer: influence on pituitary-gonadal axis and sexual function. Urology 2005; 66:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/49\">",
"      Berger CC, Bokemeyer C, Schuppert F, Schmoll HJ. Endocrinological late effects after chemotherapy for testicular cancer. Br J Cancer 1996; 73:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/50\">",
"      Strumberg D, Br&uuml;gge S, Korn MW, et al. Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann Oncol 2002; 13:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/51\">",
"      Huddart RA, Norman A, Moynihan C, et al. Fertility, gonadal and sexual function in survivors of testicular cancer. Br J Cancer 2005; 93:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/52\">",
"      Agarwal A. Semen banking in patients with cancer: 20-year experience. Int J Androl 2000; 23 Suppl 2:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/53\">",
"      van den Belt-Dusebout AW, Nuver J, de Wit R, et al. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2006; 24:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/54\">",
"      van den Belt-Dusebout AW, de Wit R, Gietema JA, et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2007; 25:4370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/55\">",
"      Huddart RA, Norman A, Shahidi M, et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 2003; 21:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/56\">",
"      Haugnes HS, Wethal T, Aass N, et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol 2010; 28:4649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/57\">",
"      Vaughn DJ, Palmer SC, Carver JR, et al. Cardiovascular risk in long-term survivors of testicular cancer. Cancer 2008; 112:1949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/58\">",
"      Altena R, de Haas EC, Nuver J, et al. Evaluation of sub-acute changes in cardiac function after cisplatin-based combination chemotherapy for testicular cancer. Br J Cancer 2009; 100:1861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/59\">",
"      Nuver J, Smit AJ, van der Meer J, et al. Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. J Clin Oncol 2005; 23:9130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/60\">",
"      Dieckmann KP, Gerl A, Witt J, et al. Myocardial infarction and other major vascular events during chemotherapy for testicular cancer. Ann Oncol 2010; 21:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/61\">",
"      Bosl GJ, Leitner SP, Atlas SA, et al. Increased plasma renin and aldosterone in patients treated with cisplatin-based chemotherapy for metastatic germ-cell tumors. J Clin Oncol 1986; 4:1684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/62\">",
"      Nuver J, Smit AJ, Wolffenbuttel BH, et al. The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol 2005; 23:3718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/63\">",
"      Nord C, Foss&aring; SD, Egeland T. Excessive annual BMI increase after chemotherapy among young survivors of testicular cancer. Br J Cancer 2003; 88:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/64\">",
"      Nuver J, Smit AJ, Sleijfer DT, et al. Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur J Cancer 2004; 40:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/65\">",
"      Gietema JA, Meinardi MT, van der Graaf WT, Sleijfer DT. Syndrome X in testicular-cancer survivors. Lancet 2001; 357:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/66\">",
"      Haugnes HS, Aass N, Foss&aring; SD, et al. Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann Oncol 2007; 18:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/67\">",
"      Raghavan D, Cox K, Childs A, et al. Hypercholesterolemia after chemotherapy for testis cancer. J Clin Oncol 1992; 10:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/68\">",
"      Gietema JA, Sleijfer DT, Willemse PH, et al. Long-term follow-up of cardiovascular risk factors in patients given chemotherapy for disseminated nonseminomatous testicular cancer. Ann Intern Med 1992; 116:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/69\">",
"      Meinardi MT, Gietema JA, van der Graaf WT, et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000; 18:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/70\">",
"      Berger CC, Bokemeyer C, Schneider M, et al. Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer. Eur J Cancer 1995; 31A:2229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/71\">",
"      Sagstuen H, Aass N, Foss&aring; SD, et al. Blood pressure and body mass index in long-term survivors of testicular cancer. J Clin Oncol 2005; 23:4980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/72\">",
"      Foss&aring; SD, Aass N, Harvei S, Tretli S. Increased mortality rates in young and middle-aged patients with malignant germ cell tumours. Br J Cancer 2004; 90:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/73\">",
"      Teutsch C, Lipton A, Harvey HA. Raynaud's phenomenon as a side effect of chemotherapy with vinblastine and bleomycin for testicular carcinoma. Cancer Treat Rep 1977; 61:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/74\">",
"      Bryd&oslash;y M, Oldenburg J, Klepp O, et al. Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors. J Natl Cancer Inst 2009; 101:1682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/75\">",
"      Glendenning JL, Barbachano Y, Norman AR, et al. Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer. Cancer 2010; 116:2322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/76\">",
"      Vogelzang NJ, Bosl GJ, Johnson K, Kennedy BJ. Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med 1981; 95:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/77\">",
"      Hantel A, Rowinsky EK, Donehower RC. Nifedipine and oncologic Raynaud phenomenon. Ann Intern Med 1988; 108:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/78\">",
"      Weijl NI, Rutten MF, Zwinderman AH, et al. Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol 2000; 18:2169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/79\">",
"      Doll DC, List AF, Greco FA, et al. Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. Ann Intern Med 1986; 105:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/80\">",
"      Cantwell BM, Mannix KA, Roberts JT, et al. Thromboembolic events during combination chemotherapy for germ cell-malignancy. Lancet 1988; 2:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/81\">",
"      Piketty AC, Fl&eacute;chon A, Laplanche A, et al. The risk of thrombo-embolic events is increased in patients with germ-cell tumours and can be predicted by serum lactate dehydrogenase and body surface area. Br J Cancer 2005; 93:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/82\">",
"      Doll DC, Ringenberg QS, Yarbro JW. Vascular toxicity associated with antineoplastic agents. J Clin Oncol 1986; 4:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/83\">",
"      Huddart RA, Norman A. Changes in BMI after treatment of testicular cancer are due to age and hormonal function and not chemotherapy. Br J Cancer 2003; 89:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/84\">",
"      Thorsen L, Nystad W, Dahl O, et al. The level of physical activity in long-term survivors of testicular cancer. Eur J Cancer 2003; 39:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/85\">",
"      Thompson SW, Davis LE, Kornfeld M, et al. Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer 1984; 54:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/86\">",
"      Hansen SW, Helweg-Larsen S, Trojaborg W. Long-term neurotoxicity in patients treated with cisplatin, vinblastine, and bleomycin for metastatic germ cell cancer. J Clin Oncol 1989; 7:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/87\">",
"      von Schlippe M, Fowler CJ, Harland SJ. Cisplatin neurotoxicity in the treatment of metastatic germ cell tumour: time course and prognosis. Br J Cancer 2001; 85:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/88\">",
"      Bokemeyer C, Berger CC, Hartmann JT, et al. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer 1998; 77:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/89\">",
"      Gratton MA, Kamen BA. Potentiation of cisplatin ototoxicity by noise. J Clin Oncol 1990; 8:2091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/90\">",
"      Travis LB, Foss&aring; SD, Schonfeld SJ, et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 2005; 97:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/91\">",
"      Robinson D, M&oslash;ller H, Horwich A. Mortality and incidence of second cancers following treatment for testicular cancer. Br J Cancer 2007; 96:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/92\">",
"      Richiardi L, Sc&eacute;lo G, Boffetta P, et al. Second malignancies among survivors of germ-cell testicular cancer: a pooled analysis between 13 cancer registries. Int J Cancer 2007; 120:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/93\">",
"      Kollmannsberger C, Hartmann JT, Kanz L, Bokemeyer C. Therapy-related malignancies following treatment of germ cell cancer. Int J Cancer 1999; 83:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/94\">",
"      Ratain MJ, Rowley JD. Therapy-related acute myeloid leukemia secondary to inhibitors of topoisomerase II: from the bedside to the target genes. Ann Oncol 1992; 3:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/95\">",
"      Bokemeyer C, Schmoll HJ. Secondary neoplasms following treatment of malignant germ cell tumors. J Clin Oncol 1993; 11:1703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/96\">",
"      Nichols CR, Breeden ES, Loehrer PJ, et al. Secondary leukemia associated with a conventional dose of etoposide: review of serial germ cell tumor protocols. J Natl Cancer Inst 1993; 85:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/97\">",
"      Pedersen-Bjergaard J, Daugaard G, Hansen SW, et al. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours. Lancet 1991; 338:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/98\">",
"      Bajorin DF, Motzer RJ, Rodriguez E, et al. Acute nonlymphocytic leukemia in germ cell tumor patients treated with etoposide-containing chemotherapy. J Natl Cancer Inst 1993; 85:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/99\">",
"      Boshoff C, Begent RH, Oliver RT, et al. Secondary tumours following etoposide containing therapy for germ cell cancer. Ann Oncol 1995; 6:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/100\">",
"      Smith MA, Rubinstein L, Anderson JR, et al. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J Clin Oncol 1999; 17:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/101\">",
"      Houck W, Abonour R, Vance G, Einhorn LH. Secondary leukemias in refractory germ cell tumor patients undergoing autologous stem-cell transplantation using high-dose etoposide. J Clin Oncol 2004; 22:2155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/102\">",
"      Schairer C, Hisada M, Chen BE, et al. Comparative mortality for 621 second cancers in 29356 testicular cancer survivors and 12420 matched first cancers. J Natl Cancer Inst 2007; 99:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/103\">",
"      Foss&aring; SD, Gilbert E, Dores GM, et al. Noncancer causes of death in survivors of testicular cancer. J Natl Cancer Inst 2007; 99:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/104\">",
"      Kollmannsberger C, Kuzcyk M, Mayer F, et al. Late toxicity following curative treatment of testicular cancer. Semin Surg Oncol 1999; 17:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/49/20250/abstract/105\">",
"      Hanks GE, Peters T, Owen J. Seminoma of the testis: long-term beneficial and deleterious results of radiation. Int J Radiat Oncol Biol Phys 1992; 24:913.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2955 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-2.133.93.82-3DA446CC7F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_49_20250=[""].join("\n");
var outline_f19_49_20250=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HEMATOLOGIC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PULMONARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Bleomycin toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Late chemotherapy toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Prevention of late pulmonary toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      RENAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Electrolyte disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Reducing nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Hemolytic uremic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      GONADAL EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Spermatogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Hormonal changes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      CARDIOVASCULAR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      The metabolic syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Hyperlipidemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Myocardial ischemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Raynaud's phenomenon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Thromboembolic events",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Changes in body metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      NEUROLOGIC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Neuropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Ototoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SECOND MALIGNANCIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Solid tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Treatment outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      NONCANCER MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2955\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2955|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/2/14382\" title=\"table 1\">",
"      Bleomycin etoposide and cisplatin regimen",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12794?source=related_link\">",
"      Bleomycin-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34137?source=related_link\">",
"      Cardiotoxicity of radiation therapy for malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=related_link\">",
"      Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13720?source=related_link\">",
"      Chapter 2B: Renin-angiotensin system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41738?source=related_link\">",
"      Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29833?source=related_link\">",
"      Cisplatin nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/48/6921?source=related_link\">",
"      Clinical manifestations and diagnosis of the Raynaud phenomenon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/42/39594?source=related_link\">",
"      Cytogenetics in acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/24/13706?source=related_link\">",
"      Effects of cytotoxic agents on gonadal function in adult men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/25/2457?source=related_link\">",
"      Epidemiology of and risk factors for testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=related_link\">",
"      Initial risk-stratified treatment for advanced testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43530?source=related_link\">",
"      Neurologic complications of non-platinum cancer chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37242?source=related_link\">",
"      Neurologic complications of platinum-based chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7337?source=related_link\">",
"      Overview of hypertension in acute and chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=related_link\">",
"      Overview of the risk equivalents and established risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13432?source=related_link\">",
"      Overview of the treatment of testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/45/9943?source=related_link\">",
"      Posttreatment follow-up for men with testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/3/9272?source=related_link\">",
"      Retroperitoneal lymph node dissection in testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33241?source=related_link\">",
"      Screening guidelines for dyslipidemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=related_link\">",
"      The metabolic syndrome (insulin resistance syndrome or syndrome X)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39480?source=related_link\">",
"      Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3610?source=related_link\">",
"      Treatment of male infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/2/22567?source=related_link\">",
"      Treatment of stage I seminoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/30/28138?source=related_link\">",
"      Treatment of the Raynaud phenomenon resistant to initial therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33945?source=related_link\">",
"      Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_49_20251="Manifestations of IgE rxns";
var content_f19_49_20251=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F79448&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F79448&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical manifestations of IgE-mediated reactions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical features:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Dermatologic:",
"        </em>",
"        Pruritus, flushing, urticaria/angioedema, diaphoresis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Eyes:",
"        </em>",
"        Conjunctival injection, lacrimation, periorbital edema, pruritus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Respiratory tract:",
"        </em>",
"        Nose/oropharynx (sneezing, rhinorrhea, nasal congestion, oral pruritus, metallic taste), upper airway (hoarseness, stridor, sense of choking, laryngeal edema), lower airway (dyspnea, tachypnea, wheezing, cough, cyanosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Cardiovascular:",
"        </em>",
"        Conduction disturbances, tachycardia, bradycardia (if severe), arrhythmias, hypotension, cardiac arrest",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Gastrointestinal:",
"        </em>",
"        Nausea/vomiting, abdominal cramping, bloating, diarrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Neurologic:",
"        </em>",
"        Sense of impending doom, syncope, dizziness, seizures",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_49_20251=[""].join("\n");
var outline_f19_49_20251=null;
var title_f19_49_20252="Definition positive TST in children";
var content_f19_49_20252=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78596&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78596&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Definitions of positive tuberculin skin test (TST) results in infants, children, and adolescents*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Induration 5 mm or greater",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Children in close contact with known or suspected contagious people with tuberculosis disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Children suspected to have tuberculosis disease:",
"        <ul>",
"         <li>",
"          Findings on chest radiograph consistent with active or previous tuberculosis disease",
"         </li>",
"         <li>",
"          Clinical evidence of tuberculosis disease",
"          <sup>",
"           &Delta;",
"          </sup>",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Children receiving immunosuppressive therapy",
"        <sup>",
"         &loz;",
"        </sup>",
"        or with immunosuppressive conditions, including human immunodeficiency (HIV) infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Induration 10 mm or greater",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Children at increased risk of disseminated tuberculosis disease:",
"        <ul>",
"         <li>",
"          Children younger than&nbsp;four years of age",
"         </li>",
"         <li>",
"          Children with other medical conditions, including Hodgkin disease, lymphoma, diabetes mellitus, chronic renal failure, or malnutrition",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Children with likelihood of increased exposure to tuberculosis disease:",
"        <ul>",
"         <li>",
"          Children born in high-prevalence regions of the world",
"         </li>",
"         <li>",
"          Children who travel to high-prevalence regions of the world",
"         </li>",
"         <li>",
"          Children frequently exposed to adults who are HIV infected, homeless, users of illicit drugs, residents of nursing homes, incarcerated, or institutionalized",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Induration 15 mm or greater",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Children age&nbsp;four years or older without any risk factors",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * These definitions apply regardless of previous bacille Calmette-Gu&eacute;rin immunization; erythema alone at TST site does not indicate a positive test result. Tests should be read at 48 to 72 hours after placement.",
"     <br/>",
"     &Delta; Evidence by physical examination or laboratory assessment that would include tuberculosis in the working differential diagnosis (eg, meningitis).",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Including immunosuppressive doses of corticosteroids or tumor necrosis factor-alpha antagonists.",
"    </div>",
"    <div class=\"reference\">",
"     From: American Academy of Pediatrics. Tuberculosis. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th ed, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. Used with the permission of the American Academy of Pediatrics. Copyright &copy; 2012.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_49_20252=[""].join("\n");
var outline_f19_49_20252=null;
var title_f19_49_20253="Risk of mortality among dial pts according to baseline albumin";
var content_f19_49_20253=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F60944&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F60944&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Risk of mortality among dialysis patients according to baseline albumin at initiation of dialysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 410px; height: 245px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Correlation of the risk of mortality according to the plasma albumin concentration obtained within six weeks of starting maintenance dialysis in 2897 patients receiving hemodialysis and 666 patients treated with continuous ambulatory peritoneal dialysis. Hypoalbuminemia was associated with increased mortality, particularly at plasma concentrations below 3.0 g/dL (30 g/L).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Held, PJ, Port, FK",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_49_20253=[""].join("\n");
var outline_f19_49_20253=null;
var title_f19_49_20254="Asthma trigger guide";
var content_f19_49_20254=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F52067&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F52067&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    How to control things that make your asthma worse",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tr>",
"          <td>",
"           You can help prevent asthma episodes by staying away from things that make your asthma worse. This guide suggests many ways to help you do this.",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           You need to find out what makes your asthma worse. Some things that make asthma worse for some people are not a problem for others. You do not need to do all of the things listed in this guide.",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Look at the things listed in dark print below. Put a check next to the ones that you know make your asthma worse, particularly if you are allergic to the things. Then, decide with your doctor what steps you will take. Start with the things in your bedroom that bother your asthma. Try something simple first.",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"subtitle1_single\">",
"           Tobacco smoke",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           If you smoke, ask your doctor for ways to help you quit. Ask family members to quit smoking, too.",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Do not allow smoking in your home, car, or around you.",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Be sure no one smokes at a child's daycare center or school.",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"subtitle1_single\">",
"           Dust mites",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Many people who have asthma are allergic to dust mites. Dust mites are like tiny \"bugs\" you cannot see that live in cloth or carpet.",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1_start\">",
"           Things that will help the most:",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Encase your mattress in a special dust miteproof cover.*",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Encase your pillow in a special dust mite-proof cover* or wash the pillow each week in hot water. Water must be hotter than 130&deg;F to kill the mites. Cooler water used with detergent and bleach can also be effective.",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Wash the sheets and blankets on your bed each week in hot water.",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1_start\">",
"           Other things that can help:",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Reduce indoor humidity to or below 60 percent; ideally 30-50 percent. Dehumidifiers or central air conditioners can do this.",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Try not to sleep or lie on cloth-covered cushions or furniture.",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Remove carpets from your bedroom and those laid on concrete, if you can.",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Keep stuffed toys out of the bed, or wash the toys weekly in hot water or in cooler water with detergent and bleach. Placing toys weekly in a dryer or freezer may help. Prolonged exposure to dry heat or freezing can kill mites but does not remove allergen.",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"subtitle1_single\">",
"           Animal dander",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Some people are allergic to the flakes of skin or dried saliva from animals.",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1_start\">",
"           The best thing to do:",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Keep animals with fur or hair out of your home.",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1_start\">",
"           If you can't keep the pet outdoors, then:",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Keep the pet out of your bedroom, and keep the bedroom door closed.",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Remove carpets and furniture covered with cloth from your home. If that is not possible, keep the pet out of the rooms where these are.",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"subtitle1_single\">",
"           Cockroach",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1_start\">",
"           Many people with asthma are allergic to the dried droppings and remains of cockroaches.",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Keep all food out of your bedroom.",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Keep food and garbage in closed containers (never leave food out).",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Use poison baits, powders, gels, or paste (for example, boric acid). You can also use traps.",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           If a spray is used to kill roaches, stay out of the room until the odor goes away.",
"          </td>",
"         </tr>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tr>",
"          <td class=\"subtitle1_single\">",
"           Vacuum cleaning",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Try to get someone else to vacuum for you once or twice a week, if you can. Stay out of rooms while they are being vacuumed and for a short while afterward.",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           If you vacuum, use a dust mask (from a hardware store), a central cleaner with the collecting bag outside the home, or a vacuum cleaner with a HEPA filter or a double-layered bag.*",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"subtitle1_single\">",
"           Indoor mold",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Fix leaking faucets, pipes, or other sources of water.",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Clean moldy surfaces.",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Dehumidify basements if possible.",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"subtitle1_single\">",
"           Pollen and outdoor mold",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1_start\">",
"           During your allergy season (when pollen or mold spore counts are high):",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Try to keep your windows closed.",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           If possible, stay indoors with windows closed during the midday and afternoon, if you can. Pollen and some mold spore counts are highest at that time.",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"sublist1\">",
"           Ask your doctor whether you need to take or increase anti-inflammatory medicine before your allergy season starts.",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"subtitle1_single\">",
"           Smoke, strong odors, and sprays",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           If possible, do not use a wood-burning stove, kerosene heater, fireplace, unvented gas stove, or heater.",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Try to stay away from strong odors and sprays, such as perfume, talcum powder, hair spray, paints, new carpet, or particle board.",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"subtitle1_single\">",
"           Exercise or sports",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           You should be able to be active without symptoms. See your doctor if you have asthma symptoms when you are active-such as when you exercise, do sports, play, or work hard.",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Ask your doctor about taking medicine before you exercise to prevent symptoms.",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Warm up for a period before you exercise.",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Check the air quality index and try not to work or play hard outside when the air pollution or pollen levels (if you are allergic to the pollen) are high.",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"subtitle1_single\">",
"           Other things that can make asthma worse",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Sulfites in foods: do not drink beer or wine or eat shrimp, dried fruit, or processed potatoes if they cause asthma symptoms.",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Cold air: cover your nose and mouth with a scarf on cold or windy days.",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Other medicines: tell your doctor about all the medicines you may take. Include cold medicines, aspirin, and even eye drops.",
"          </td>",
"         </tr>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     <strong>",
"      * To find out where to get products mentioned in this guide, call:",
"     </strong>",
"     <br>",
"      Asthma and Allergy Foundation of America (800-727-8462).",
"      <br>",
"       Allergy and Asthma Network/Mothers of Asthmatics, Inc. (800-878-4403).",
"       <br>",
"        American Academy of Allergy, Asthma, and Immunology (800-822-2762).",
"        <br>",
"         National Jewish Medical and Research Center (Lung Line) (800-222-5864).",
"         <br>",
"          American College of Allergy, Asthma, and Immunology (800-842-7777).",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_49_20254=[""].join("\n");
var outline_f19_49_20254=null;
var title_f19_49_20255="Chest radiograph Ebstein";
var content_f19_49_20255=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68211&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68211&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chest radiograph in Ebstein anomaly",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 368px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The chest radiograph of a patient with Ebstein anomaly shows a very large cardiac silhouette. The prominence of the right cardiac border represents a markedly dilated right atrium (red arrow). The left cardiac border, instead of displaying the usual outlines of the aortic arch and pulmonary artery trunk, is abnormally convex and protuberant due to the border-forming, laterally displaced, and dilated right ventricular outflow tract (white arrow); the aortic knot and pulmonary artery trunk are not visible. Intrapulmonary vessels are smaller and fewer than normal leading to reduced pulmonary flow.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_49_20255=[""].join("\n");
var outline_f19_49_20255=null;
          